Cardiotoxicity in anthracycline therapy: Prevention strategies | Revista Portuguesa de Cardiologia (English edition)

array:25 ["pii" => "S2174204916300642" "issn" => "21742049" "doi" => "10.1016/j.repce.2015.12.020" "estado" => "S300" "fechaPublicacion" => "2016-06-01" "aid" => "786" "copyright" => "Sociedade Portuguesa de Cardiologia" "copyrightAnyo" => "2016" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "ssu" "cita" => "Rev Port Cardiol. 2016;35:359-71" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5702 "formatos" => array:3 [ "EPUB" => 189 "HTML" => 4366 "PDF" => 1147 ] ] "Traduccion" => array:1 [ "pt" => array:20 [ "pii" => "S0870255116000627" "issn" => "08702551" "doi" => "10.1016/j.repc.2015.12.004" "estado" => "S300" "fechaPublicacion" => "2016-06-01" "aid" => "786" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "ssu" "cita" => "Rev Port Cardiol. 2016;35:359-71" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 14963 "formatos" => array:3 [ "EPUB" => 229 "HTML" => 12977 "PDF" => 1757 ] ] "pt" => array:13 [ "idiomaDefecto" => true "cabecera" => "Artigo de revisão" "titulo" => "Cardiotoxicidade na terapêutica com antraciclinas: estratégias de prevenção" "tienePdf" => "pt" "tieneTextoCompleto" => "pt" "tieneResumen" => array:2 [ 0 => "pt" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "359" "paginaFinal" => "371" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Cardiotoxicity in anthracycline therapy: Prevention strategies" ] ] "contieneResumen" => array:2 [ "pt" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "pt" => true ] "contienePdf" => array:1 [ "pt" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2397 "Ancho" => 2412 "Tamanyo" => 317784 ] ] "descripcion" => array:1 [ "pt" => "Iniciação de um regime potencialmente associado a cardiotoxicidade por antraciclinas. Eco2D: ecocardiograma 2D; Eco3D: ecocardiograma 3D; FEVE: fração de ejeção do ventrículo esquerdo; GLS: global longitudinal strain; LIN: limite inferior do normal." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Margarida Cruz, Joana Duarte‐Rodrigues, Manuel Campelo" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Margarida" "apellidos" => "Cruz" ] 1 => array:2 [ "nombre" => "Joana" "apellidos" => "Duarte‐Rodrigues" ] 2 => array:2 [ "nombre" => "Manuel" "apellidos" => "Campelo" ] ] ] ] ] "idiomaDefecto" => "pt" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2174204916300642" "doi" => "10.1016/j.repce.2015.12.020" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204916300642?idApp=UINPBA00004E" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255116000627?idApp=UINPBA00004E" "url" => "/08702551/0000003500000006/v1_201606140033/S0870255116000627/v1_201606140033/pt/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S2174204916300290" "issn" => "21742049" "doi" => "10.1016/j.repce.2015.09.027" "estado" => "S300" "fechaPublicacion" => "2016-06-01" "aid" => "737" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Rev Port Cardiol. 2016;35:373.e1-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4484 "formatos" => array:3 [ "EPUB" => 202 "HTML" => 3586 "PDF" => 696 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Case report" "titulo" => "Left ventricular pseudoaneurysm – a challenging diagnosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "373.e1" "paginaFinal" => "373.e6" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Pseudoaneurisma ventricular esquerdo – um desafio diagnóstico" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 737 "Ancho" => 2500 "Tamanyo" => 290630 ] ] "descripcion" => array:1 [ "en" => "(A) Repair of the pseudoaneurysm (arrow) by the modified Dor procedure; (B) exclusion of the pseudoaneurysm with a Dacron patch (arrowhead) and Teflon strips; (C) final result." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Mariana Faustino, Sara Ranchordás, João Abecasis, António Freitas, Moradas Ferreira, Victor Gil, Carlos Morais, José Pedro Neves" "autores" => array:8 [ 0 => array:2 [ "nombre" => "Mariana" "apellidos" => "Faustino" ] 1 => array:2 [ "nombre" => "Sara" "apellidos" => "Ranchordás" ] 2 => array:2 [ "nombre" => "João" "apellidos" => "Abecasis" ] 3 => array:2 [ "nombre" => "António" "apellidos" => "Freitas" ] 4 => array:2 [ "nombre" => "Moradas" "apellidos" => "Ferreira" ] 5 => array:2 [ "nombre" => "Victor" "apellidos" => "Gil" ] 6 => array:2 [ "nombre" => "Carlos" "apellidos" => "Morais" ] 7 => array:2 [ "nombre" => "José Pedro" "apellidos" => "Neves" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "pt" => array:9 [ "pii" => "S0870255115003169" "doi" => "10.1016/j.repc.2015.09.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255115003169?idApp=UINPBA00004E" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204916300290?idApp=UINPBA00004E" "url" => "/21742049/0000003500000006/v2_201704050129/S2174204916300290/v2_201704050129/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S2174204916300320" "issn" => "21742049" "doi" => "10.1016/j.repce.2015.12.019" "estado" => "S300" "fechaPublicacion" => "2016-06-01" "aid" => "787" "copyright" => "Sociedade Portuguesa de Cardiologia" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Rev Port Cardiol. 2016;35:351-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3063 "formatos" => array:3 [ "EPUB" => 171 "HTML" => 2329 "PDF" => 563 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "Original Article" "titulo" => "Cardiac device infection: Review based on the experience of a single center" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "351" "paginaFinal" => "358" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Endocardite de dispositivos, revisão com base na experiência de um centro" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Andreia Fernandes, Miryan Cassandra, Joana Trigo, José Nascimento, Maria Carmo Cachulo, Rui Providência, Marco Costa, Lino Gonçalves" "autores" => array:8 [ 0 => array:2 [ "nombre" => "Andreia" "apellidos" => "Fernandes" ] 1 => array:2 [ "nombre" => "Miryan" "apellidos" => "Cassandra" ] 2 => array:2 [ "nombre" => "Joana" "apellidos" => "Trigo" ] 3 => array:2 [ "nombre" => "José" "apellidos" => "Nascimento" ] 4 => array:2 [ "nombre" => "Maria" "apellidos" => "Carmo Cachulo" ] 5 => array:2 [ "nombre" => "Rui" "apellidos" => "Providência" ] 6 => array:2 [ "nombre" => "Marco" "apellidos" => "Costa" ] 7 => array:2 [ "nombre" => "Lino" "apellidos" => "Gonçalves" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "pt" => array:9 [ "pii" => "S0870255116000639" "doi" => "10.1016/j.repc.2015.12.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255116000639?idApp=UINPBA00004E" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204916300320?idApp=UINPBA00004E" "url" => "/21742049/0000003500000006/v2_201704050129/S2174204916300320/v2_201704050129/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "Review article" "titulo" => "Cardiotoxicity in anthracycline therapy: Prevention strategies" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "359" "paginaFinal" => "371" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Margarida Cruz, Joana Duarte-Rodrigues, Manuel Campelo" "autores" => array:3 [ 0 => array:3 [ "nombre" => "Margarida" "apellidos" => "Cruz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "Joana" "apellidos" => "Duarte-Rodrigues" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:4 [ "nombre" => "Manuel" "apellidos" => "Campelo" "email" => array:1 [ 0 => "mcampelo@hotmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Faculdade de Medicina, Universidade do Porto, Porto, Portugal" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Serviço de Cardiologia, Hospital de S. João, Porto, Portugal" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Cardiotoxicidade na terapêutica com antraciclinas: estratégias de prevenção" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2375 "Ancho" => 2417 "Tamanyo" => 282865 ] ] "descripcion" => array:1 [ "en" => "Initiation of a regimen potentially associated with anthracycline-induced cardiotoxicity. 2DE: two-dimensional echocardiography; 3DE: three-dimensional echocardiography; GLS: global longitudinal strain; LLN: lower limit of normal; LVEF: left ventricular ejection fraction." ] ] ] "textoCompleto" => "IntroductionAccording to the World Health Organization, cancer is the second leading cause of death worldwide.<a class="elsevierStyleCrossRef" href="#bib0005">1</a> The considerable and ongoing advances in treatment have increased survival of cancer patients, but the adverse effects of chemotherapy, particularly on the heart, are a significant cause of mortality and morbidity. Mortality among cancer patients who develop anthracycline-induced cardiomyopathy is high (over 60% at two years),<a class="elsevierStyleCrossRef" href="#bib0010">2</a> but prognosis can be improved by early detection and prevention.Anthracyclines such as doxorubicin, daunorubicin, epirubicin, mitoxantrone and idarubicin are the most commonly used chemotherapy drugs in cancer. They are a known cause of cardiotoxicity (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>), with acute or/and subacute effects that can manifest as electrocardiographic changes, ventricular and supraventricular arrhythmias, cardiac conduction disturbances (atrioventricular or branch block), ventricular dysfunction, rises in brain-type natriuretic peptide (BNP, a marker of increased preload and heart failure [HF]), myocarditis and pericarditis, and that may occur at any time between beginning of treatment and two weeks after the end of treatment. These effects are relatively uncommon and most revert a week after treatment cessation. Chronic cardiomyopathy is defined as early if it begins within a year of ending chemotherapy and late after that period. In either case, systolic or diastolic dysfunction are observed (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>) that can progress to severe cardiomyopathy and may even lead to death.<a class="elsevierStyleCrossRef" href="#bib0015">3</a> Although some studies have suggested that the risk of developing ventricular dysfunction and its severity can be predicted on the basis of acute myocardial injury,<a class="elsevierStyleCrossRef" href="#bib0020">4</a> the relationship between acute and chronic toxicity is not fully understood. Diagnosis of cardiac dysfunction induced by cancer therapy has been the subject of various studies,<a class="elsevierStyleCrossRefs" href="#bib0015">3,5</a> one of which<a class="elsevierStyleCrossRef" href="#bib0025">5</a> is considered the reference publication on the subject, and is based on HF symptoms, physical examination and parameters of left ventricular function.<elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia>One proposed classification divides chemotherapy-induced cardiomyopathy into two types: type I, caused by anthracyclines, which induce irreversible dose-dependent cardiac injury; and type II, caused by trastuzumab, which is not related to the cumulative dose and is often reversible after treatment discontinuation.<a class="elsevierStyleCrossRef" href="#bib0030">6</a> The second type will not be discussed in this review article.In this review the authors discuss strategies in patients being treated with anthracyclines in order to prevent or mitigate their main adverse effects on the heart.Initial assessmentIn view of the cardiotoxicity of anthracyclines, all patients referred for chemotherapy should undergo a cardiac assessment to establish their baseline cardiovascular characteristics, which can then be used during the treatment regimen for purposes of comparison. This assessment should include clinical history and physical examination, electrocardiography to determine cardiac rhythm and detect signs of ischemia, and cardiac imaging, usually transthoracic echocardiography with complete Doppler study (<a class="elsevierStyleCrossRefs" href="#tbl0015">Tables 3 and 4</a>). When the echocardiogram is provides insufficient information, cardiac magnetic resonance imaging (CMRI) is recommended. Baseline troponin levels should also be measured for future comparisons.<a class="elsevierStyleCrossRef" href="#bib0025">5</a><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><elsevierMultimedia ident="tbl0025"></elsevierMultimedia>Monitoring during therapyIt is important to monitor for signs and symptoms of cardiotoxicity during chemotherapy (<a class="elsevierStyleCrossRef" href="#tbl0030">Table 5</a>). The 12-lead electrocardiogram can be used routinely to screen for arrhythmias due to anthracycline-related cardiotoxicity, while 24-hour Holter monitoring or an event recorder can be useful to investigate the etiology of syncope presumed to result from arrhythmia or advanced atrioventricular block.<a class="elsevierStyleCrossRef" href="#bib0035">7</a> Cardiac function should be monitored by echocardiography in patients under anthracycline therapy. Global longitudinal strain (GLS) as assessed by two-dimensional speckle tracking is a more sensitive predictor of HF than left ventricular ejection fraction (LVEF),<a class="elsevierStyleCrossRef" href="#bib0040">8</a> since during anthracycline therapy changes in GLS precede reduction in LVEF.<a class="elsevierStyleCrossRef" href="#bib0025">5</a> However, in clinical practice, fractional shortening and LVEF have been the most widely used parameters,<a class="elsevierStyleCrossRef" href="#bib0045">9</a> although fractional shortening is proving to be less reliable in this context. These parameters, being dependent on pre- and afterload, are less sensitive for early detection of preclinical cardiac disease. Various studies have suggested that assessment of diastolic function by Doppler echocardiography may enable early detection of anthracycline-induced cardiomyopathy.<a class="elsevierStyleCrossRefs" href="#bib0050">10,11</a> If LVEF is <53%, GLS below the limit of normal (<a class="elsevierStyleCrossRef" href="#tbl0035">Table 6</a>), and/or troponins are elevated, a cardiology consultation should be considered, with discussion between the cardiologist and oncologist of the risk/benefit ratio of chemotherapy.<a class="elsevierStyleCrossRef" href="#bib0025">5</a> A fall in LVEF during anthracycline therapy is associated with increased risk for cardiac events, and although a reduction in GLS of <8% compared to baseline appears not to be significant, a reduction of >15% is likely to indicate cardiotoxicity.<a class="elsevierStyleCrossRef" href="#bib0025">5</a> The study should be repeated two to three weeks after the baseline study to confirm the diagnosis. CMRI can detect subtle changes in the myocardium and increases in extracellular volume, which suggest edema or diffuse fibrosis. Although it is highly sensitive and reproducible for assessment of cardiac function and characterization of myocardial tissue, CMRI has the disadvantages of limited availability and high cost.<a class="elsevierStyleCrossRef" href="#bib0060">12</a> Radionuclide angiography is reproducible and more easily available, but exposes patients to ionizing radiation, increasing their cumulative dose, especially when serial studies are required, and provides only limited information on diastolic function and valve morphology, and so should not be the method of choice.<a class="elsevierStyleCrossRef" href="#bib0060">12</a> Endomyocardial biopsy has greater sensitivity and specificity for detection and monitoring of the adverse effects of anthracyclines,<a class="elsevierStyleCrossRef" href="#bib0025">5</a> enabling visualization of loss of myofibrils, vacuolization of cytoplasm, dilatation of the sarcoplasmic reticulum, increased numbers of lysosomes and mitochondrial swelling.<a class="elsevierStyleCrossRef" href="#bib0060">12</a> However, the invasive nature of the procedure limits its use in clinical practice. Biomarkers have been validated in various studies; they are specific not only in detecting cardiovascular injury but also in determining its extent and reversibility. While troponin T and I are indicators of cardiomyocyte damage, BNP and the N-terminal portion of pro-BNP (NT-proBNP) reflect increased myocardial stress.<a class="elsevierStyleCrossRefs" href="#bib0065">13,14</a> According to the literature, elevation of troponins is an early indicator of cardiotoxicity, while BNP is less consistent.<elsevierMultimedia ident="tbl0030"></elsevierMultimedia><elsevierMultimedia ident="tbl0035"></elsevierMultimedia>If the dose of anthracyclines exceeds 240 mg/m2, cardiac assessment should be repeated before administering further cycles (<a class="elsevierStyleCrossRef" href="#fig0005">Figure 1</a>).<elsevierMultimedia ident="fig0005"></elsevierMultimedia>Prevention of cardiotoxicityPrevention of anthracycline-induced cardiotoxicity, while maintaining the drugs’ therapeutic effectiveness, can be achieved by pharmacological and non-pharmacological means.Non-pharmacological preventionCardiovascular risk factors should be identified and treated appropriately as soon as cancer is diagnosed. Patients should be encouraged to adopt a healthy lifestyle, including a diet low in saturated fat and a maximum of 2.5 g of sodium per day, avoid toxic substances such as alcohol and tobacco, and maintain their body mass index close to 25 kg/m2. Exercise, whether of low or high intensity, during anthracycline therapy increases cardiovascular reserve<a class="elsevierStyleCrossRef" href="#bib0075">15</a> and studies in animal models have indicated that it may reduce the cardiotoxic effects of these agents.<a class="elsevierStyleCrossRef" href="#bib0080">16</a> Although exercise has shown promise in improving cardiopulmonary function in breast cancer survivors,<a class="elsevierStyleCrossRefs" href="#bib0085">17,18</a> there have been no clinical trials in humans that confirm their cardioprotective role. Another measure is to reduce or avoid the use of drugs that prolong QT interval, particularly 5-hydroxytryptamine 3 antagonists (frequently used to prevent adverse effects of chemotherapy including nausea and vomiting) and antihistamines.<a class="elsevierStyleCrossRefs" href="#bib0095">19,20</a> It is also important to minimize radiation exposure, to correct electrolyte disturbances and to treat comorbidities (<a class="elsevierStyleCrossRef" href="#tbl0040">Table 7</a>).<a class="elsevierStyleCrossRef" href="#bib0105">21</a><elsevierMultimedia ident="tbl0040"></elsevierMultimedia>Decreasing the dose of anthracyclines is another way to reduce the incidence of left ventricular systolic dysfunction (LVSD), as shown by a study of patients taking 400, 500 or 550 mg/m2 of doxorubicin, in which the incidence of congestive HF was 5%, 16% and 26% respectively.<a class="elsevierStyleCrossRef" href="#bib0110">22</a> Although anthracyclines appear to be cardiotoxic independently of the dose administered, several studies have shown that continuous infusion of lower doses for between 24 and 92 hours<a class="elsevierStyleCrossRef" href="#bib0115">23</a> can reduce the severity of cardiac injury, and has been described as an effective way of doing so.<a class="elsevierStyleCrossRef" href="#bib0120">24</a> Prolonging infusion time reduces cardiotoxicity without compromising the effectiveness of chemotherapy,<a class="elsevierStyleCrossRef" href="#bib0125">25</a> but infusion lasting longer than 96 hours is associated with a high incidence of stomatitis. The only case in which continuous infusion of doxorubicin appears to have no cardioprotective effect compared to rapid infusion is in children with acute lymphoblastic leukemia (ALL).<a class="elsevierStyleCrossRef" href="#bib0130">26</a> Other clinical trials using endomyocardial biopsy to assess anthracycline-induced cardiac injury in different drug regimens concluded that continuous perfusion leads to far less significant damage than rapid intravenous administration.<a class="elsevierStyleCrossRef" href="#bib0135">27</a> These trials also showed that patients receiving continuous infusion had greater tolerance for higher cumulative doses of doxorubicin. Although animal studies demonstrated that anthracycline levels in tumor tissue were the same however the drugs were administered (continuous or rapid infusion), this was not true of cardiac tissue, in which rapid infusion led to higher concentrations and thus greater toxicity.<a class="elsevierStyleCrossRef" href="#bib0140">28</a>Pharmacological preventionAntioxidantsAlthough antioxidants neutralize free radicals formed by anthracycline therapy and thus theoretically reduce or prevent cardiotoxicity, clinical trials of N-acetylcysteine, coenzyme Q, L-carnitine, phenethylamines, amifostine and a combination of vitamins E and C and N-acetylcysteine did not show a cardioprotective effect.<a class="elsevierStyleCrossRef" href="#bib0145">29</a> Erythropoietin and iloprost<a class="elsevierStyleCrossRef" href="#bib0150">30</a> have been shown to protect against the cardiotoxic effects of doxorubicin in vitro, without affecting its anticancer effectiveness, but their cardioprotective ability will have to be demonstrated in vivo.Liposomal formulationsOne way to combat the adverse cardiac effects of anthracyclines is to change the formulation of the drugs such as encapsulating them in liposomes.<a class="elsevierStyleCrossRef" href="#bib0155">31</a> Studies comparing unencapsulated and liposome-encapsulated doxorubicin found no difference in anti-tumor response rate, overall survival or progression-free survival, but the incidence of HF and LVSD was lower in patients treated with the liposomal formulation, and this group also had a lower incidence of other adverse effects including neutropenia, nausea, vomiting and diarrhea.<a class="elsevierStyleCrossRef" href="#bib0160">32</a> Due to their high cost, these formulations are not widely used and the US Food and Drug Administration (FDA) has approved their use only for ovarian cancer, AIDS-related Kaposi's sarcoma, and patients with multiple myeloma who have not responded to a year of treatment with other drugs.<a class="elsevierStyleCrossRef" href="#bib0165">33</a>DexrazoxaneAdministration of dexrazoxane concomitantly with anticancer regimens can have a cardioprotective effect, preventing elevation of troponins and reducing the incidence of HF.<a class="elsevierStyleCrossRef" href="#bib0170">34</a> Some authors attribute the cardioprotective effect of this iron chelator to its reduction of the quantity of intracellular iron, which may decrease doxorubicin-induced free radical generation.<a class="elsevierStyleCrossRef" href="#bib0170">34</a> However, studies on other iron chelators have not demonstrated cardioprotection.<a class="elsevierStyleCrossRefs" href="#bib0175">35,36</a> It has also been suggested that dexrazoxane's cardioprotective effect is due not only to its antagonizing topoisomerase II cleavage complex formation, but also to its induction of rapid degradation of topoisomerase II beta, which suggests that this enzyme is involved in anthracycline-induced cardiotoxicity.<a class="elsevierStyleCrossRef" href="#bib0185">37</a> A study of dexrazoxane in over 200 children with ALL showed that it reduced troponin T elevation in both sexes,<a class="elsevierStyleCrossRef" href="#bib0190">38</a> and limited reduction of fractional shortening and maintained left ventricular thickness-to-dimension ratio at five years, but only in girls.<a class="elsevierStyleCrossRef" href="#bib0195">39</a> Recently three cases have been reported of adults undergoing chemotherapy combined with dexrazoxane for breast cancer who developed acute myeloid leukemia. However, two studies comparing dexrazoxane with placebo in children with ALL followed for five and 10 years showed no difference in the incidence of secondary malignancy.<a class="elsevierStyleCrossRefs" href="#bib0200">40,41</a> Nevertheless, in view of its known adverse effects, the FDA and the European Medicines Agency have restricted the use of dexrazoxane to adult patients with advanced or metastatic breast cancer who have already received a cumulative dose of doxorubicin of more than 300 mg/m2 and who will benefit from additional anthracycline therapy.<a class="elsevierStyleCrossRef" href="#bib0210">42</a>Beta-blockersThe cardioprotection afforded by beta-blockers (BBs) appears to derive from their antioxidant and anti-apoptotic properties. One BB, carvedilol, has shown particular promise in reducing the incidence of anthracycline-induced cardiomyopathy and preserving systolic and diastolic function.<a class="elsevierStyleCrossRef" href="#bib0215">43</a> In children, carvedilol limited troponin I elevation and improved both fractional shortening and peak global systolic strain.<a class="elsevierStyleCrossRef" href="#bib0220">44</a> According to some studies, BBs and angiotensin-converting enzyme (ACE) inhibitors (see below) can prevent the remodeling associated with HF by reducing adrenergic response.<a class="elsevierStyleCrossRefs" href="#bib0225">45,46</a> However, no cardioprotective effects have been seen with either metoprolol or enalapril.<a class="elsevierStyleCrossRef" href="#bib0235">47</a>Angiotensin-converting enzyme inhibitors and angiotensin receptor blockersACE inhibitors and angiotensin receptor blockers (ARBs) show cardioprotective properties, possibly by reducing oxidative stress, left ventricular remodeling, and apoptosis.<a class="elsevierStyleCrossRef" href="#bib0240">48</a> When administered for at least two years after discontinuation of chemotherapy in children with anthracycline-induced LVSD, enalapril showed no benefit in terms of reducing left ventricular end-systolic wall stress or preserving fractional shortening.<a class="elsevierStyleCrossRef" href="#bib0245">49</a> By contrast, in adults treated with high-dose anthracyclines, enalapril prevented HF and worsening of parameters of cardiac function such as LVEF.<a class="elsevierStyleCrossRef" href="#bib0250">50</a> Studies in angiotensin II type I receptor knockout mice showed that doxorubicin did not have a cardiotoxic effect in these animals and that the administration of ARBs can prevent daunorobucin-induced cardiomyopathy.<a class="elsevierStyleCrossRef" href="#bib0240">48</a> Although to our knowledge there have been only two randomized trials on ARBs in chemotherapy patients, valsartan was shown to prevent acute prolongation of corrected QT, left ventricular diastolic dilatation and elevation of BNP during one week of chemotherapy, although with no effect on LVEF,<a class="elsevierStyleCrossRef" href="#bib0255">51</a> and telmisartan prevented reduction in peak strain rate during high-dose anthracycline therapy.<a class="elsevierStyleCrossRef" href="#bib0260">52</a> Further studies are required with longer follow-up to confirm these effects.StatinsStatins have antioxidant and anti-inflammatory properties.<a class="elsevierStyleCrossRef" href="#bib0265">53</a> Studies in animal models demonstrate that fluvastatin mitigates anthracycline-induced cardiotoxicity, reducing oxidative stress and enhancing the expression of the antioxidant enzyme mitochondrial superoxide dismutase 2, resulting in reduced cardiac inflammation.<a class="elsevierStyleCrossRef" href="#bib0265">53</a> In one clinical trial assessing the effect of continuous statin treatment in patients with breast cancer receiving anthracycline-based chemotherapy, patients receiving statins had a lower incidence of HF.<a class="elsevierStyleCrossRef" href="#bib0270">54</a> In another study in patients with previously normal LVEF undergoing anthracycline chemotherapy, LVEF was unchanged at six months in those treated with atorvastatin, compared to a fall of 8% in the control group.<a class="elsevierStyleCrossRef" href="#bib0275">55</a>Finally, it should be emphasized that there is as yet no solid evidence for the effectiveness of pharmacological prevention of anthracycline-induced cardiomyopathy, and so the main preventive strategy remains thorough prior cardiovascular assessment of patients and appropriate monitoring, selection and adjustment of chemotherapy dosages.Treatment of heart failureAfter the development of signs or symptoms of HF or a reduction in LVEF due to chemotherapy-related cardiotoxicity, treatment should be based on the current guidelines.<a class="elsevierStyleCrossRef" href="#bib0280">56</a> Although selection of the best therapy is obviously important, one study has shown that the main factor determining successful treatment is the time between the end of chemotherapy and the start of HF therapy, since if this is longer than six months, LVEF is unlikely to recover completely.<a class="elsevierStyleCrossRef" href="#bib0285">57</a>Prospects for the futureSeveral clinical trials are currently under way aiming to assess various therapeutic strategies, pharmacological and non-pharmacological, for the prevention of anthracycline-induced cardiomyopathy (<a class="elsevierStyleCrossRef" href="#tbl0045">Table 8</a>). It will be some years before the results are known, and there is still a pressing need for evidence-based guidelines for the assessment and clinical monitoring of these patients.<elsevierMultimedia ident="tbl0045"></elsevierMultimedia>ConclusionThe longer survival of patients undergoing anticancer therapy and the consequent increase in the incidence of anthracycline-induced cardiomyopathy mean that it is necessary to investigate and determine the precise mechanisms leading to adverse cardiac effects, in order to prevent them. Further research will enable specific and validated prevention plans to be established.Conflicts of interestThe authors have no conflicts of interest to declare." "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres824756" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec821215" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres824757" "titulo" => "Resumo" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec821214" "titulo" => "Palavras-chave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Initial assessment" "secciones" => array:1 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Monitoring during therapy" ] ] ] 6 => array:3 [ "identificador" => "sec0020" "titulo" => "Prevention of cardiotoxicity" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0025" "titulo" => "Non-pharmacological prevention" ] 1 => array:3 [ "identificador" => "sec0030" "titulo" => "Pharmacological prevention" "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0035" "titulo" => "Antioxidants" ] 1 => array:2 [ "identificador" => "sec0040" "titulo" => "Liposomal formulations" ] 2 => array:2 [ "identificador" => "sec0045" "titulo" => "Dexrazoxane" ] 3 => array:2 [ "identificador" => "sec0050" "titulo" => "Beta-blockers" ] 4 => array:2 [ "identificador" => "sec0055" "titulo" => "Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers" ] 5 => array:2 [ "identificador" => "sec0060" "titulo" => "Statins" ] ] ] ] ] 7 => array:2 [ "identificador" => "sec0065" "titulo" => "Treatment of heart failure" ] 8 => array:2 [ "identificador" => "sec0070" "titulo" => "Prospects for the future" ] 9 => array:2 [ "identificador" => "sec0075" "titulo" => "Conclusion" ] 10 => array:2 [ "identificador" => "sec0080" "titulo" => "Conflicts of interest" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2015-07-27" "fechaAceptado" => "2015-12-20" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec821215" "palabras" => array:4 [ 0 => "Anthracyclines" 1 => "Cardiotoxicity" 2 => "Prevention" 3 => "Chemotherapy" ] ] ] "pt" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palavras-chave" "identificador" => "xpalclavsec821214" "palabras" => array:4 [ 0 => "Antraciclinas" 1 => "Cardiotoxicidade" 2 => "Prevenção" 3 => "Quimioterapia" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "The increasing use of anthracyclines, together with the longer survival of cancer patients, means the toxic effects of these drugs need to be monitored. In order to detect, prevent or mitigate anthracycline-induced cardiomyopathy, it is essential that all patients undergo a rigorous initial cardiovascular assessment, followed by close monitoring. Several clinical trials have shown the cardioprotective effect of non-pharmacological measures such as exercise, healthy lifestyles, control of risk factors and treatment of comorbidities; a cardioprotective effect has also been observed with pharmacological measures such as beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, statins, dexrazoxane and liposomal formulations. However, there are currently no guidelines for managing prevention in these patients. In this review the authors discuss the state of the art of the assessment, monitoring, and, above all, the prevention of anthracycline-induced cardiotoxicity." ] "pt" => array:2 [ "titulo" => "Resumo" "resumen" => "O crescente uso de antraciclinas, aliado ao aumento da sobrevida dos doentes oncológicos, motiva a necessidade de monitorizar os efeitos tóxicos destes fármacos. Para que a sua cardiotoxicidade possa ser detetada, prevenida ou atenuada, torna-se essencial que todos os doentes sejam, do ponto de vista cardiovascular, submetidos a uma rigorosa avaliação inicial e a um estreito acompanhamento. Diversos ensaios clínicos comprovaram o efeito cardioprotetor produzido por medidas não farmacológicas como o exercício físico, a adoção de um estilo de vida saudável, o controlo de fatores de risco e o tratamento de comorbilidades; foi também verificado um efeito cardioprotetor com estratégias farmacológicas como o uso de bloqueadores-beta, inibidores da enzima de conversão da angiotensina, antagonistas do recetor da angiotensina, estatinas, dexrazoxane ou derivados lisossomais. No entanto, atualmente não existe qualquer diretriz científica que oriente as estratégias de prevenção nestes doentes. Com esta revisão propomo-nos abordar o estado da arte relativo à avaliação, monitorização e, principalmente, à prevenção da cardiotoxicidade provocada pelas antraciclinas." ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Cruz M, Duarte-Rodrigues J, Campelo M. Cardiotoxicidade na terapêutica com antraciclinas: estratégias de prevenção. Rev Port Cardiol. 2016;35:359–371." ] ] "multimedia" => array:9 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2375 "Ancho" => 2417 "Tamanyo" => 282865 ] ] "descripcion" => array:1 [ "en" => "Initiation of a regimen potentially associated with anthracycline-induced cardiotoxicity. 2DE: two-dimensional echocardiography; 3DE: three-dimensional echocardiography; GLS: global longitudinal strain; LLN: lower limit of normal; LVEF: left ventricular ejection fraction." ] ] 1 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "AV: atrioventricular.Adapted from <a class="elsevierStyleCrossRefs" href="#bib0120">24,58,59</a>." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Mechanisms of action \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Mechanisms of cardiotoxicity \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Anthracycline \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Therapeutic use \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Cardiotoxicity \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " rowspan="5" align="left" valign="middle">The formation of a DNA complex by conjugation of flat rings with nucleotides inhibits DNA and RNA and protein synthesis. This triggers DNA cleavage by topoisomerase II, resulting in cytotoxicity. Anthracyclines inhibit helicase, preventing enzymatic cleavage of the DNA double strand and thus interfering with replication and transcription. They cause redox reactions through formation of cytotoxic free radicals.</td><td class="td" title="table-entry " rowspan="5" align="left" valign="middle">Main mechanisms: - topoisomerase II beta-mediated DNA damage - lipid peroxidation - oxidative stress - apoptosis and necrosis of cardiac cells Impaired synthesis of DNA, RNA and proteins and of transcription factors involved in regulation of genes specific to the heart. Negative balance of sarcomeric proteins in cardiac cells caused by reduced protein expression and increased myofilament degradation. Combination therapy exacerbates myofilament loss. Mitochondrial DNA damage and changes in mitochondrial bioenergetics. Disruption of the dynamic regulation of cardiac function, altering adrenergic and adenylyl cyclase activity and calcium homeostasis.</td><td class="td" title="table-entry " align="left" valign="middle">Doxorubicin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="middle">Advanced stomach cancer Bladder cancer Breast cancer Ovarian cancer Small cell lung cancer Thyroid cancer Hodgkin disease Acute leukemia Non-Hodgkin lymphoma Neuroblastoma Sarcoma Wilms tumor \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Acute: Hypotension Arrhythmias Tachycardia Thromboembolism Subacute: Pericarditis Myocarditis Chronic: Dilated cardiomyopathy Contractile dysfunction Congestive heart failure \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="middle">Daunorubicin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="middle">Acute lymphoblastic leukemia Acute myeloid leukemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Acute: Sinus tachycardia Tachyarrhythmias Ventricular extrasystoles AV block Chronic: Dilated cardiomyopathy Contractile dysfunction Congestive heart failure \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="middle">Epirubicin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="middle">Advanced ovarian cancer Stomach cancer Breast cancer Lung cancer \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Acute: Ventricular tachycardia AV block Bundle branch block Bradycardia Thromboembolism Chronic: Dilated cardiomyopathy Contractile dysfunction Congestive heart failure \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="middle">Idarubicin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="middle">Acute lymphocytic leukemia Acute myeloid leukemia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Acute: Arrhythmias Atrial fibrillation Myocardial infarction Thromboembolism Chronic: Dilated cardiomyopathy Contractile dysfunction Congestive heart failure \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="left" valign="middle">Mitoxantrone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="middle">Advanced breast cancer Acute myeloid leukemia in adults Non-Hodgkin lymphoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Acute: Arrhythmias Myocarditis Hypertension Myocardial ischemia Chronic: Dilated cardiomyopathy Contractile dysfunction Congestive heart failure \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1386611.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Cardiotoxicity, pharmacokinetics and therapeutic use of anthracyclines." ] ] 2 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "CHF: congestive heart failure; LVEF: left ventricular ejection fraction.Adapted from <a class="elsevierStyleCrossRefs" href="#bib0015">3,60</a>." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Any one of the criteria is sufficient to confirm a diagnosis of cardiac dysfunction. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Cardiomyopathy characterized by a decrease in cardiac LVEF that is either global or more severe in the septum \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Symptoms of CHF \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Detection of S3 gallop, tachycardia, or both; \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Decline in LVEF of at least 5% to less than 55% with accompanying signs or symptoms of CHF, or a decline in LVEF of at least 10% to below 55% without accompanying signs or symptoms. \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1386613.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Criteria to confirm or revise a preliminary diagnosis of chemotherapy-induced cardiac dysfunction, according to the Cardiac Review and Evaluation Committee." ] ] 3 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at3" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "Adapted from <a class="elsevierStyleCrossRef" href="#bib0025">5</a>.2D: two-dimensional; 3D: three-dimensional; ASE/EAE: American Society of Echocardiography/European Association of Echocardiography; BP: blood pressure; GLS: global longitudinal strain; HR: heart rate; IAC-Echo: Intersocietal Accreditation Commission Echocardiography; IV: intravenous; LV: left ventricular; LVEF: left ventricular ejection fraction; MAPSE: mitral annular plane systolic excursion; RV: right ventricle; TAPSE: tricuspid annular plane systolic excursion; VTI: velocity-time integral." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Standard transthoracic echocardiography \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• In accordance with ASE/EAE guidelines and IAC-Echo \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">2D strain imaging acquisition \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Apical 3-, 4-, and 2-chamber views \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Acquire ≥3 cardiac cycles \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Images obtained simultaneously maintaining the same 2D frame rate and imaging depth \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Frame rate between 40 and 90 frames/s or ≥40% of HR \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Aortic VTI (aortic ejection time) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">2D strain imaging analysis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Quantify segmental and global longitudinal strain \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Display the segmental strain curves from apical views in a quad format \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Display the global strain in a bull's-eye plot \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">2D strain imaging pitfalls \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Ectopy \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Breathing translation \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">3D imaging acquisition \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Apical 4-chamber full volume to assess LV volumes and to calculate LVEF \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Single and multiple beats optimizing spatial and temporal resolution \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Reporting \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Timing of echocardiography with respect to the IV infusion (number of days before or after) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Vital signs (BP, HR) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• 3D LVEF/2D biplane Simpson method \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• GLS (echocardiography machine, software, and version used) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• In the absence of GLS, measurement of medial and lateral s′ and MAPSE \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• RV: TAPSE \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1386612.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Recommended cardio-oncology echocardiogram protocol." ] ] 4 => array:8 [ "identificador" => "tbl0025" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at4" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "Adapted from <a class="elsevierStyleCrossRef" href="#bib0025">5</a>.2DE: two-dimensional echocardiography; 3DE: three-dimensional echocardiography; ASE/EAE: American Society of Echocardiography/European Association of Echocardiography; GLS: global longitudinal strain; LV: left ventricular; LVEF: left ventricular ejection fraction; STE: speckle-tracking echocardiography; TDI: tissue Doppler imaging." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">LV systolic function \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Echocardiography is the method of choice for the assessment of patients before, during and after cancer therapy. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Accurate calculation of LVEF should be done with the best method available in the echocardiography laboratory (ideally 3DE). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• When using 2DE, the modified biplane Simpson technique is the method of choice. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• LVEF should be combined with the calculation of wall motion score index. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• In the absence of GLS by STE, quantification of LV longitudinal function using MAPSE and/or peak systolic velocity (s′) of the mitral annulus by pulsed-wave TDI is recommended. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• LVEF assessed by 2DE often fails to detect small changes in LV contractility. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Diastolic function \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">• Although diastolic parameters have not been found to be prognostic of anthracycline-induced cardiomyopathy, a conventional assessment of LV diastolic function, including grading of diastolic function and non-invasive estimation of LV filling pressures, should be added to the assessment of LV systolic function, according to ASE/EAE recommendations for the evaluation of LV diastolic function with echocardiography. \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1386610.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Echocardiographical assessment of systolic and diastolic function in the cancer patient." ] ] 5 => array:8 [ "identificador" => "tbl0030" "etiqueta" => "Table 5" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at5" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "Adapted from <a class="elsevierStyleCrossRefs" href="#bib0025">5,12,61</a>.2D: two-dimensional; CAD: coronary artery disease; CV: cardiovascular; ECG: electrocardiography; GFR: glomerular filtration rate; GLS: global longitudinal strain; HF: heart failure; LV: left ventricular; LVEF: left ventricular ejection fraction." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Diagnostic exam \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Advantages \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Disadvantages \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Electrocardiography \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Non-invasive Low cost Measures QT interval, prolongation of which is a known marker of cardiotoxicity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Does not measure LVEF Intra- and inter-observer variability in measurement of QT interval \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Doppler echocardiography \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Non-invasive Low cost Assessment of functional and morphological diastolic (pulmonary venous flow, E/A ratio, isovolumic relaxation time) and systolic (wall thickening during systole, LVEF, fractional shortening) parameters, valve structure and pericardium \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Intra- and inter-observer variability Measurement of LVEF subject to variability and dependent on image quality Doubtful predictive value for early detection of subclinical lesions \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Tissue Doppler imaging \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Excellent temporal resolution Early detection of subclinical lesions (in combination with markers of inflammation and oxidative stress) Functional assessment of filling pressures (E/e′ ratio), velocities, strain and strain rate of ventricular walls in systole and diastole Detection of isolated diastolic dysfunction \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">More time-consuming analysis \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">2D strain/speckle tracking and GLS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Superior to LVEF for predicting cardiovascular mortality in the general population Better risk stratification in HF patients Able to recognize early LV dysfunction in patients undergoing cardiotoxic therapy Reproducible when performed by an experienced operator \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Heavily dependent on image quality of 2D echocardiography Lack of long-term clinical trials assessing the ability of GLS to predict persistent falls in LVEF or symptomatic HF \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Stress echocardiography \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Assessment of myocardial contractile reserve \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Semi-invasive Controversial and limited data on early detection of cardiotoxicity \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Radionuclide angiography \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">High reproducibility Low intra- and inter-observer variability Validated for measurement of LVEF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Ionizing radiation Low spatial and temporal resolution Underestimates ventricular volumes Underestimates LVEF in small ventricles (women and children) Does not assess valve function Little information on diastolic function Limited predictive value for early detection of subclinical lesions and changes in LVEF \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Magnetic resonance imaging \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Reproducible No ionizing radiation Assessment of myocardial perfusion and function and pericardium, and detection of myocardial masses Useful in patients with poor echocardiographic image quality Gold standard for calculation of LV volumes and of LVEF T2 sequences: detects segmental or global changes in myocardial water content resulting from inflammation or microvascular or myocyte damage T1 sequences: provides information on myocardial lesions and fibrosis; with gadolinium contrast, detects histopathological alterations including intracellular vacuolization, enabling prediction of subsequent decrease in LVEF Late enhancement: detection of myocardial fibrosis associated with poor prognosis in patients with CAD, hypertrophic cardiomyopathy and infiltrative disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">High cost Limited availability Contraindicated in patients with devices incompatible with magnetic resonance (pacemakers, cardiac resynchronization devices and implantable cardioverter-defibrillators) Risk of contrast nephrotoxicity in patients with renal failure (GFR <30 ml/min) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Computed tomography \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">High-resolution image Identifies pericardial calcification or thickening in patients undergoing radiotherapy or surgery Visualizes and assesses calcification of the coronary arteries \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Ionizing radiation Documented coronary calcification prior to anticancer therapy is not predictive of CV risk in patients undergoing anthracycline chemotherapy Little used for detection and monitoring of subclinical changes in cardiac function \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Scintigraphy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Non-invasive Functional and structural assessment \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Ionizing radiation Limited availability Low temporal resolution Limited data \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Biomarkers \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Non-invasive Low inter-observer variability Assessment of CV function and potential signs of cardiac damage Promising for early detection of myocardial injury \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Undetermined predictive value \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Endomyocardial biopsy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Detects histological evidence of cardiac damage, including loss of myofibrils, vacuolization of cytoplasm, dilatation of the sarcoplasmic reticulum, increased numbers of lysosomes and mitochondrial swelling \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Invasive Histological interpretation requires specialist knowledge No functional information Results limited by quantity and quality of biopsy sample \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Assessment of endothelial damage \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Alternate parameters of cardiotoxicity such as cytokines, adhesion molecules and carotid artery intima-media thickness \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Undetermined predictive value \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Genetic analysis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Minimally invasive Assesses individual susceptibility to cardiotoxicity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Undetermined predictive value. \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1386609.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Advantages and disadvantages of diagnostic exams in the assessment of anthracycline-induced cardiotoxicity." ] ] 6 => array:8 [ "identificador" => "tbl0035" "etiqueta" => "Table 6" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at6" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "V1: Vivid 7 or Vivid E9 (GE Healthcare); V2: iE33 (Philips Medical Systems); V3: Artida or Apilo (Toshiba Medical Systems).Adapted from <a class="elsevierStyleCrossRef" href="#bib0310">62</a>." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="7" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Age (years)</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">0-19 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">20-29 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">30-39 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">40-49 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">50-59 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">≥65 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">p \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " colspan="8" align="left" valign="top">V1</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Overall \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-22.1±2.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-21.2±1.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-21.1±2.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-21.4±2.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-21.0±2.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.3±1.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.0218 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Male \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-21.7±3.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.9±1.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.6±1.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.9±1.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-21.0±1.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-19.7±1.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.1982 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Female \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-22.4±1.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-22.3±1.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-22.8±1.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-22.6±2.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-23.3±1.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.9±2.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.0348 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">p (male vs. female) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.4292 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.0316 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.0001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.0178 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.0029 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.1381 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="8" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="8" align="left" valign="top">V2</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Overall \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-19.9±2.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-19.0±2.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-19.5±2.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-18.2±2.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-17.6±2.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-16.7±2.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.0001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Male \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-19.4±2.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-18.8±2.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-19.1±2.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-17.9±2.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-16.9±2.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-15.8±1.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.0019 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Female \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.5±2.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.6±2.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.2±2.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-19.3±0.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.4±1.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-17.3±2.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.0002 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">p (male vs. female) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.1349 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.0248 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.1083 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.4316 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.0294 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.0928 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="8" align="left" valign="top"></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="8" align="left" valign="top">V3</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Overall \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-21.4±1.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.2±2.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.4±2.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-19.4±2.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-18.5±2.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-17.8±2.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.0001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Male \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-21.6±2.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.2±2.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.4±2.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-19.8±2.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-18.7±2.6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-16.3±3.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.0001 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Female \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-21.2±1.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.2±2.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-20.4±2.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-18.7±1.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-18.3±2.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">-18.6±2.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.0141 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">p (male vs. female) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.6076 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.9787 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.9201 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.1415 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.7374 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.0668 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1386614.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Normal values of global longitudinal strain by vendor of scanner, gender, and age." ] ] 7 => array:8 [ "identificador" => "tbl0040" "etiqueta" => "Table 7" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at7" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "CV: cardiovascular." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Cumulative doses exceeding: \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " colspan="2" align="left" valign="top">Recommended maximum (mg/m2)<a class="elsevierStyleCrossRef" href="#tblfn0005">a</a>:</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Doxorubicin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">400-550 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Daunorubicin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">550-800 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Epirubicin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">900-1000 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Idarubicin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">150-225 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Mitoxantrone \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100-140 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Pre-existing CV disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " colspan="2" align="left" valign="top">Diabetes</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " colspan="2" align="left" valign="top">Coronary artery disease</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " colspan="2" align="left" valign="top">Peripheral vascular disease</td></tr><tr title="table-row"><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " colspan="2" align="left" valign="top">Hypertension</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top">Genetic predisposition: female gender, black race</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top">Previous or concomitant mediastinal radiation</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top">Intravenous bolus administration</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top">Combination with other agents including cyclophosphamide, trastuzumab or paclitaxel</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top">Length of time since end of chemotherapy</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top">Electrolyte disturbances: hypocalcemia, hypomagnesemia</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top">Hemochromatosis (C282Y mutation)</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top">Hyperthermia</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top">Liver disease</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1386615.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "Patients aged over 65 and children may develop cardiotoxicity with lower cumulative doses. Adapted from <a class="elsevierStyleCrossRefs" href="#bib0060">12,24</a>." ] ] ] "descripcion" => array:1 [ "en" => "Risk factors for anthracycline-induced cardiotoxicity." ] ] 8 => array:8 [ "identificador" => "tbl0045" "etiqueta" => "Table 8" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at8" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "CT: computed tomography; GLS: global longitudinal strain; LVDF: left ventricular diastolic function; LVEF: left ventricular ejection fraction; LVSD: left ventricular systolic dysfunction; MRI: magnetic resonance imaging." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Lead author and ClinicalTrials.gov no. \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Type of trial \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Condition \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Chemotherapy agent(s) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Intervention \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">No. of patients \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Follow-up \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Primary outcome measure \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Planned trial conclusion \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Mavrudis D NCT01120171 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Randomized, phase 2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Breast cancer \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Anthracyclines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cyclophosphamide vs. liposome-encapsulated doxorubicin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">48 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Overall response rate by CT or MRI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">May 2015 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Campbell K NCT02006979 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Single blind, phase 2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Breast cancer \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Anthracyclines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">An acute bout of exercise performed 24 hours prior to every anthracycline infusion \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 year \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">GLS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">December 2015 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Cipolla C NCT01968200 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Randomized, phase 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cancer \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Anthracyclines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Enalapril after appearance of cardiac injury vs. enalapril concomitantly to chemotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">268 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Up to one year after completion of chemotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cardiac troponin levels \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">July 2016 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Virani S NCT01708798 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Double blind, phase 2, 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Breast cancer \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Anthracyclines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Eplerenone vs. placebo \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">78 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Change in LVDF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">May 2015 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Bocchi E NCT01724450 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Double blind, phase 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Breast cancer \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Anthracyclines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Carvedilol vs. placebo \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">200 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">LVSD (10% reduction in LVEF) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">October 2016 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Livi L NCT02236806 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Single blind, phase 3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Breast cancer \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Anthracyclines and trastuzumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Bisoprolol vs. ramipril, bisoprolol vs. placebo, ramipril vs. placebo \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">480 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 year \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">LVEF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">November 2017 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Smith K NCT02096588 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Randomized, phase 2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Breast cancer \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Anthracyclines \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Simvastatin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">90 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">GLS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">April 2021 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1386608.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Clinical trials on prevention of anthracycline-induced cardiomyopathy." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:62 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Projections of global mortality and burden of disease from 2002 to 2030" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "C.D. Mathers" 1 => "D. Loncar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pmed.0030442" "Revista" => array:5 [ "tituloSerie" => "PLoS Med" "fecha" => "2006" "volumen" => "3" "paginaInicial" => "e442" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17132052" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFACOT Registry) – EURObservational Research Program of the European Society of Cardiology" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "P. Lancellotti" 1 => "S.D. Anker" 2 => "E. Donal" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Soc Echocardiogr" "fecha" => "2015" "volumen" => "16" "paginaInicial" => "466" "paginaFinal" => "470" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "A. Albini" 1 => "G. Pennesi" 2 => "F. Donatelli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jnci/djp440" "Revista" => array:6 [ "tituloSerie" => "J Natl Cancer Inst" "fecha" => "2010" "volumen" => "102" "paginaInicial" => "14" "paginaFinal" => "25" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20007921" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "D. Cardinale" 1 => "M.T. Sandri" 2 => "A. Martinoni" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2000" "volumen" => "36" "paginaInicial" => "517" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10933366" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J.C. Plana" 1 => "M. Galderisi" 2 => "A. Barac" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.echo.2014.07.012" "Revista" => array:6 [ "tituloSerie" => "J Am Soc Echocardiogr" "fecha" => "2014" "volumen" => "27" "paginaInicial" => "911" "paginaFinal" => "939" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25172399" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of chemotherapy induced cardiomyopathy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "A. Saidi" 1 => "R. Alharethi" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Curr Cardiol Rev" "fecha" => "2011" "volumen" => "7" "paginaInicial" => "245" "paginaFinal" => "249" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22758625" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0039606015003177" "estado" => "S300" "issn" => "00396060" ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part IV: The ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "P.M. Rautaharju" 1 => "B. Surawicz" 2 => "L.S. Gettes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2008.12.014" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2009" "volumen" => "53" "paginaInicial" => "982" "paginaFinal" => "991" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19281931" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemotherapy-induced cardiotoxicity: detection, prevention, and management" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. Truong" 1 => "A.T. Yan" 2 => "G. Cramarossa" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cjca.2014.04.029" "Revista" => array:6 [ "tituloSerie" => "Can J Cardiol" "fecha" => "2014" "volumen" => "30" "paginaInicial" => "869" "paginaFinal" => "878" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25064580" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Doxorubicin-induced congestive heart failure in adults" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M.M. Haq" 1 => "S.S. Legha" 2 => "J. Choksi" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cancer" "fecha" => "1985" "volumen" => "56" "paginaInicial" => "1361" "paginaFinal" => "1365" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/4027874" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiac diastolic function in pediatric patients receiving doxorubicin" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M.S. Ewer" 1 => "M.K. Ali" 2 => "H.R. Gibbs" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Acta Oncol" "fecha" => "1994" "volumen" => "33" "paginaInicial" => "645" "paginaFinal" => "649" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7946442" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "B. Marchandise" 1 => "E. Schroeder" 2 => "A. Bosly" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Am Heart J" "fecha" => "1989" "volumen" => "118" "paginaInicial" => "92" "paginaFinal" => "98" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2741800" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "E. Raschi" 1 => "V. Vasina" 2 => "M.G. Ursino" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.pharmthera.2009.10.002" "Revista" => array:6 [ "tituloSerie" => "Pharmacol Ther" "fecha" => "2010" "volumen" => "125" "paginaInicial" => "196" "paginaFinal" => "218" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19874849" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R.G. Schwartz" 1 => "D. Jain" 2 => "E. Storozynsky" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12350-013-9707-1" "Revista" => array:6 [ "tituloSerie" => "J Nucl Cardiol" "fecha" => "2013" "volumen" => "20" "paginaInicial" => "443" "paginaFinal" => "464" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23572315" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Early detection of treatment induced cardiac toxicity – can we do better?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.M. Lombard" 1 => "R. Paterson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ajco.12085" "Revista" => array:6 [ "tituloSerie" => "Asia Pac J Clin Oncol" "fecha" => "2013" "volumen" => "9" "paginaInicial" => "97" "paginaFinal" => "98" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23682667" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J.M. Scott" 1 => "A. Khakoo" 2 => "J.R. Mackey" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/CIRCULATIONAHA.111.021774" "Revista" => array:6 [ "tituloSerie" => "Circulation" "fecha" => "2011" "volumen" => "124" "paginaInicial" => "642" "paginaFinal" => "650" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21810673" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "A.J. Chicco" 1 => "D.S. Hydock" 2 => "C.M. Schneider" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Appl Physiol (Bethesda, MD: 1985)" "fecha" => "2006" "volumen" => "100" "paginaInicial" => "519" "paginaFinal" => "527" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "K.S. Courneya" 1 => "J.R. Mackey" 2 => "G.J. Bell" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2003.04.093" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2003" "volumen" => "21" "paginaInicial" => "1660" "paginaFinal" => "1668" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12721239" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "L.W. Jones" 1 => "N.D. Eves" 2 => "M. Haykowsky" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1470-2045(09)70031-2" "Revista" => array:6 [ "tituloSerie" => "Lancet Oncol" "fecha" => "2009" "volumen" => "10" "paginaInicial" => "598" "paginaFinal" => "605" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19482248" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Molecularly targeted oncology therapeutics and prolongation of the QT interval" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "E.L. Strevel" 1 => "D.J. Ing" 2 => "L.L. Siu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2006.09.6925" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2007" "volumen" => "25" "paginaInicial" => "3362" "paginaFinal" => "3371" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17664484" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "interval prolongation in cancer patients" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "T.K. Becker" 1 => "S.C.J. Yeung" 2 => "Q.T. Drug-induced" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Oncol Rev" "fecha" => "2010" "volumen" => "4" "paginaInicial" => "223" "paginaFinal" => "232" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "G. Curigliano" 1 => "D. Cardinale" 2 => "T. Suter" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/annonc/mds293" "Revista" => array:7 [ "tituloSerie" => "Ann Oncol" "fecha" => "2012" "volumen" => "23" "numero" => "Suppl. 7" "paginaInicial" => "vii155" "paginaFinal" => "vii166" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22997448" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S.M. Swain" 1 => "F.S. Whaley" 2 => "M.S. Ewer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/cncr.11407" "Revista" => array:6 [ "tituloSerie" => "Cancer" "fecha" => "2003" "volumen" => "97" "paginaInicial" => "2869" "paginaFinal" => "2879" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12767102" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "E.T. Yeh" 1 => "A.T. Tong" 2 => "D.J. Lenihan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/01.CIR.0000133187.74800.B9" "Revista" => array:7 [ "tituloSerie" => "Circulation." "fecha" => "2004" "volumen" => "109" "numero" => "25" "paginaInicial" => "3122" "paginaFinal" => "3131" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15226229" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "R. Adão" 1 => "G. de Keulenaer" 2 => "A. Leite-Moreira" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.repc.2012.11.002" "Revista" => array:6 [ "tituloSerie" => "Rev Port Cardiol" "fecha" => "2013" "volumen" => "32" "paginaInicial" => "395" "paginaFinal" => "409" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23623503" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S.S. Legha" 1 => "R.S. Benjamin" 2 => "B. Mackay" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Intern Med" "fecha" => "1982" "volumen" => "96" "paginaInicial" => "133" "paginaFinal" => "139" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7059060" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S.E. Lipshultz" 1 => "T.L. Miller" 2 => "S.R. Lipsitz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1542/peds.2012-0727" "Revista" => array:6 [ "tituloSerie" => "Pediatrics" "fecha" => "2012" "volumen" => "130" "paginaInicial" => "1003" "paginaFinal" => "1011" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23166343" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M. Valdivieso" 1 => "M.A. Burgess" 2 => "M.S. Ewer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.1984.2.3.207" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "1984" "volumen" => "2" "paginaInicial" => "207" "paginaFinal" => "214" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/6321689" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M.A. Pacciarini" 1 => "B. Barbieri" 2 => "T. Colombo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cancer Treat Rep" "fecha" => "1978" "volumen" => "62" "paginaInicial" => "791" "paginaFinal" => "800" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/657163" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "CD003917" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardioprotective interventions for cancer patients receiving anthracyclines" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "E.C. van Dalen" 1 => "H.N. Caron" 2 => "H.O. Dickinson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/14651858.CD003917.pub4" "Revista" => array:2 [ "tituloSerie" => "Cochrane Database Syst Rev" "fecha" => "2011" ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S. Hamed" 1 => "I. Barshack" 2 => "G. Luboshits" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehl044" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2006" "volumen" => "27" "paginaInicial" => "1876" "paginaFinal" => "1883" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16731534" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "F.M. Muggia" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Drugs" "fecha" => "1997" "volumen" => "54" "numero" => "Suppl. 4" "paginaInicial" => "22" "paginaFinal" => "29" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9361958" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "CD005006" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Different anthracycline derivates for reducing cardiotoxicity in cancer patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "E.C. van Dalen" 1 => "E.M. Michiels" 2 => "H.N. Caron" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/14651858.CD005006.pub3" "Revista" => array:2 [ "tituloSerie" => "Cochrane Database Syst Rev" "fecha" => "2010" ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "U.S. Food and Drug Administration. Drug safety and availability. FDA statement on DOXIL® (doxorubicin HCl liposome injection) for intravenous infusion. Available at: <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050718s043lbl.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050718s043lbl.pdf</a> [accessed 27.01.15]." ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "M.L. Hensley" 1 => "L.M. Schuchter" 2 => "C. Lindley" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.1999.17.10.3333" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "1999" "volumen" => "17" "paginaInicial" => "3333" "paginaFinal" => "3355" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10506637" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "E. Martin" 1 => "A.V. Thougaard" 2 => "M. Grauslund" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.tox.2008.10.011" "Revista" => array:6 [ "tituloSerie" => "Toxicology" "fecha" => "2009" "volumen" => "255" "paginaInicial" => "72" "paginaFinal" => "79" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19010377" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0180" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "B.B. Hasinoff" 1 => "D. Patel" 2 => "X. Wu" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Free Radic Biol Med" "fecha" => "2003" "volumen" => "35" "paginaInicial" => "1469" "paginaFinal" => "1479" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14642395" "web" => "Medline" ] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0185" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Y.L. Lyu" 1 => "J.E. Kerrigan" 2 => "C.P. Lin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1158/0008-5472.CAN-07-1649" "Revista" => array:6 [ "tituloSerie" => "Cancer Res" "fecha" => "2007" "volumen" => "67" "paginaInicial" => "8839" "paginaFinal" => "8846" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17875725" "web" => "Medline" ] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0190" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S.E. Lipshultz" 1 => "N. Rifai" 2 => "V.M. Dalton" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa035153" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2004" "volumen" => "351" "paginaInicial" => "145" "paginaFinal" => "153" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15247354" "web" => "Medline" ] ] ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0195" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S.E. Lipshultz" 1 => "R.E. Scully" 2 => "S.R. Lipsitz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1470-2045(10)70204-7" "Revista" => array:6 [ "tituloSerie" => "Lancet Oncol" "fecha" => "2010" "volumen" => "11" "paginaInicial" => "950" "paginaFinal" => "961" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20850381" "web" => "Medline" ] ] ] ] ] ] ] ] 39 => array:3 [ "identificador" => "bib0200" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "W.L. Salzer" 1 => "M. Devidas" 2 => "W.L. Carroll" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1038/leu.2009.261" "Revista" => array:6 [ "tituloSerie" => "Leukemia" "fecha" => "2010" "volumen" => "24" "paginaInicial" => "355" "paginaFinal" => "370" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20016527" "web" => "Medline" ] ] ] ] ] ] ] ] 40 => array:3 [ "identificador" => "bib0205" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "L.M. Vrooman" 1 => "D.S. Neuberg" 2 => "K.E. Stevenson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejca.2011.03.022" "Revista" => array:6 [ "tituloSerie" => "Eur J Cancer" "fecha" => "2011" "volumen" => "47" "paginaInicial" => "1373" "paginaFinal" => "1379" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21514146" "web" => "Medline" ] ] ] ] ] ] ] ] 41 => array:3 [ "identificador" => "bib0210" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "FDA Statement on Dexrazoxane; 2011. Available at: <a href="http://www.fda.gov/Drugs/DrugSafety/ucm263729.htm">http://www.fda.gov/Drugs/DrugSafety/ucm263729.htm</a> [cited 28.02.15]." ] ] ] 42 => array:3 [ "identificador" => "bib0215" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "P. Spallarossa" 1 => "S. Garibaldi" 2 => "P. Altieri" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.yjmcc.2004.05.024" "Revista" => array:6 [ "tituloSerie" => "J Mol Cell Cardiol" "fecha" => "2004" "volumen" => "37" "paginaInicial" => "837" "paginaFinal" => "846" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15380674" "web" => "Medline" ] ] ] ] ] ] ] ] 43 => array:3 [ "identificador" => "bib0220" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "N.A. El-Shitany" 1 => "O.A. Tolba" 2 => "M.R. El-Shanshory" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cardfail.2012.06.416" "Revista" => array:6 [ "tituloSerie" => "J Card Fail" "fecha" => "2012" "volumen" => "18" "paginaInicial" => "607" "paginaFinal" => "613" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22858075" "web" => "Medline" ] ] ] ] ] ] ] ] 44 => array:3 [ "identificador" => "bib0225" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R. Garg" 1 => "S. Yusuf" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Med Assoc" "fecha" => "1995" "volumen" => "273" "paginaInicial" => "1450" "paginaFinal" => "1456" ] ] ] ] ] ] 45 => array:3 [ "identificador" => "bib0230" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "A. Hjalmarson" 1 => "S. Goldstein" 2 => "B. Fagerberg" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Med Assoc" "fecha" => "2000" "volumen" => "283" "paginaInicial" => "1295" "paginaFinal" => "1302" ] ] ] ] ] ] 46 => array:3 [ "identificador" => "bib0235" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "P. Georgakopoulos" 1 => "P. Roussou" 2 => "E. Matsakas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ajh.21840" "Revista" => array:6 [ "tituloSerie" => "Am J Hematol" "fecha" => "2010" "volumen" => "85" "paginaInicial" => "894" "paginaFinal" => "896" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20872550" "web" => "Medline" ] ] ] ] ] ] ] ] 47 => array:3 [ "identificador" => "bib0240" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "H. Toko" 1 => "T. Oka" 2 => "Y. Zou" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Hypertens Res" "fecha" => "2002" "volumen" => "25" "paginaInicial" => "597" "paginaFinal" => "603" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12358147" "web" => "Medline" ] ] ] ] ] ] ] ] 48 => array:3 [ "identificador" => "bib0245" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J.H. Silber" 1 => "A. Cnaan" 2 => "B.J. Clark" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2004.06.022" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2004" "volumen" => "22" "paginaInicial" => "820" "paginaFinal" => "828" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14990637" "web" => "Medline" ] ] ] ] ] ] ] ] 49 => array:3 [ "identificador" => "bib0250" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "D. Cardinale" 1 => "A. Colombo" 2 => "M.T. Sandri" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/CIRCULATIONAHA.106.635144" "Revista" => array:6 [ "tituloSerie" => "Circulation" "fecha" => "2006" "volumen" => "114" "paginaInicial" => "2474" "paginaFinal" => "2481" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17101852" "web" => "Medline" ] ] ] ] ] ] ] ] 50 => array:3 [ "identificador" => "bib0255" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "H. Nakamae" 1 => "K. Tsumura" 2 => "Y. Terada" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/cncr.21478" "Revista" => array:6 [ "tituloSerie" => "Cancer" "fecha" => "2005" "volumen" => "104" "paginaInicial" => "2492" "paginaFinal" => "2498" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16247790" "web" => "Medline" ] ] ] ] ] ] ] ] 51 => array:3 [ "identificador" => "bib0260" "etiqueta" => "52" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "487.e1–7" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C. Cadeddu" 1 => "A. Piras" 2 => "G. Mantovani" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Am Heart J" "fecha" => "2010" "volumen" => "160" ] ] ] ] ] ] 52 => array:3 [ "identificador" => "bib0265" "etiqueta" => "53" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "A. Riad" 1 => "S. Bien" 2 => "D. Westermann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1158/0008-5472.CAN-08-3076" "Revista" => array:6 [ "tituloSerie" => "Cancer Res" "fecha" => "2009" "volumen" => "69" "paginaInicial" => "695" "paginaFinal" => "699" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19147586" "web" => "Medline" ] ] ] ] ] ] ] ] 53 => array:3 [ "identificador" => "bib0270" "etiqueta" => "54" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S. Seicean" 1 => "A. Seicean" 2 => "J.C. Plana" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2012.07.067" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2012" "volumen" => "60" "paginaInicial" => "2384" "paginaFinal" => "2390" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23141499" "web" => "Medline" ] ] ] ] ] ] ] ] 54 => array:3 [ "identificador" => "bib0275" "etiqueta" => "55" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Z. Acar" 1 => "A. Kale" 2 => "M. Turgut" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2011.05.025" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2011" "volumen" => "58" "paginaInicial" => "988" "paginaFinal" => "989" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21851890" "web" => "Medline" ] ] ] ] ] ] ] ] 55 => array:3 [ "identificador" => "bib0280" "etiqueta" => "56" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D. Bovelli" 1 => "G. Plataniotis" 2 => "F. Roila" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/annonc/mdq200" "Revista" => array:7 [ "tituloSerie" => "Ann Oncol" "fecha" => "2010" "volumen" => "21" "numero" => "Suppl. 5" "paginaInicial" => "v277" "paginaFinal" => "v282" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20555097" "web" => "Medline" ] ] ] ] ] ] ] ] 56 => array:3 [ "identificador" => "bib0285" "etiqueta" => "57" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "D. Cardinale" 1 => "A. Colombo" 2 => "G. Lamantia" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacc.2009.03.095" "Revista" => array:6 [ "tituloSerie" => "J Am Coll Cardiol" "fecha" => "2010" "volumen" => "55" "paginaInicial" => "213" "paginaFinal" => "220" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20117401" "web" => "Medline" ] ] ] ] ] ] ] ] 57 => array:3 [ "identificador" => "bib0290" "etiqueta" => "58" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Supercoiling of the DNA template during transcription" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "L.F. Liu" 1 => "J.C. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Proc Natl Acad Sci U S A" "fecha" => "1987" "volumen" => "84" "paginaInicial" => "7024" "paginaFinal" => "7027" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2823250" "web" => "Medline" ] ] ] ] ] ] ] ] 58 => array:3 [ "identificador" => "bib0295" "etiqueta" => "59" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "V. Machado" 1 => "A. Cabral" 2 => "P. Monteiro" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Port Cardiol" "fecha" => "2008" "volumen" => "27" "paginaInicial" => "1277" "paginaFinal" => "1296" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19178029" "web" => "Medline" ] ] ] ] ] ] ] ] 59 => array:3 [ "identificador" => "bib0300" "etiqueta" => "60" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cardiac dysfunction in the trastuzumab clinical trials experience" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "A. Seidman" 1 => "C. Hudis" 2 => "M.K. Pierri" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2002.20.5.1215" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2002" "volumen" => "20" "paginaInicial" => "1215" "paginaFinal" => "1221" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11870163" "web" => "Medline" ] ] ] ] ] ] ] ] 60 => array:3 [ "identificador" => "bib0305" "etiqueta" => "61" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Noninvasive imaging of cardiovascular injury related to the treatment of cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S. Kongbundansuk" 1 => "W.G. Hundley" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Am Coll Cardiol Imaging" "fecha" => "2014" "volumen" => "7" "paginaInicial" => "824" "paginaFinal" => "838" ] ] ] ] ] ] 61 => array:3 [ "identificador" => "bib0310" "etiqueta" => "62" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Normal range of left ventricular 2-dimensional strain: Japanese Ultrasound Speckle Tracking of the Left Ventricle (JUSTICE) study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "K. Takigiku" 1 => "M. Takeuchi" 2 => "C. Izumi" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Circ J" "fecha" => "2012" "volumen" => "76" "paginaInicial" => "2623" "paginaFinal" => "2632" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22813873" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21742049/0000003500000006/v2_201704050129/S2174204916300642/v2_201704050129/en/main.assets" "Apartado" => array:4 [ "identificador" => "9924" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Review Article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21742049/0000003500000006/v2_201704050129/S2174204916300642/v2_201704050129/en/main.pdf?idApp=UINPBA00004E&text.app=https://revportcardiol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204916300642?idApp=UINPBA00004E"]

Statistics

Review article

Cardiotoxicity in anthracycline therapy: Prevention strategies

Cardiotoxicidade na terapêutica com antraciclinas: estratégias de prevenção

Margarida Cruza, Joana Duarte-Rodriguesb, Manuel Campeloa,b,

Corresponding author

mcampelo@hotmail.com

Corresponding author.

a Faculdade de Medicina, Universidade do Porto, Porto, Portugal

b Serviço de Cardiologia, Hospital de S. João, Porto, Portugal

Read

10751

Times
was read the article

2774

Total PDF

7977

Total HTML

Share statistics

 array:25 [
  "pii" => "S2174204916300642"
  "issn" => "21742049"
  "doi" => "10.1016/j.repce.2015.12.020"
  "estado" => "S300"
  "fechaPublicacion" => "2016-06-01"
  "aid" => "786"
  "copyright" => "Sociedade Portuguesa de Cardiologia"
  "copyrightAnyo" => "2016"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "ssu"
  "cita" => "Rev Port Cardiol. 2016;35:359-71"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 5702
    "formatos" => array:3 [
      "EPUB" => 189
      "HTML" => 4366
      "PDF" => 1147
    ]
  ]
  "Traduccion" => array:1 [
    "pt" => array:20 [
      "pii" => "S0870255116000627"
      "issn" => "08702551"
      "doi" => "10.1016/j.repc.2015.12.004"
      "estado" => "S300"
      "fechaPublicacion" => "2016-06-01"
      "aid" => "786"
      "copyright" => "Sociedade Portuguesa de Cardiologia"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "ssu"
      "cita" => "Rev Port Cardiol. 2016;35:359-71"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 14963
        "formatos" => array:3 [
          "EPUB" => 229
          "HTML" => 12977
          "PDF" => 1757
        ]
      ]
      "pt" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Artigo de revis&#227;o</span>"
        "titulo" => "Cardiotoxicidade na terap&#234;utica com antraciclinas&#58; estrat&#233;gias de preven&#231;&#227;o"
        "tienePdf" => "pt"
        "tieneTextoCompleto" => "pt"
        "tieneResumen" => array:2 [
          0 => "pt"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "359"
            "paginaFinal" => "371"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Cardiotoxicity in anthracycline therapy&#58; Prevention strategies"
          ]
        ]
        "contieneResumen" => array:2 [
          "pt" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "pt" => true
        ]
        "contienePdf" => array:1 [
          "pt" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figura 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 2397
                "Ancho" => 2412
                "Tamanyo" => 317784
              ]
            ]
            "descripcion" => array:1 [
              "pt" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Inicia&#231;&#227;o de um regime potencialmente associado a cardiotoxicidade por antraciclinas&#46;</p> <p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Eco2<span class="elsevierStyleHsp" style=""></span>D&#58; ecocardiograma 2<span class="elsevierStyleHsp" style=""></span>D&#59; Eco3<span class="elsevierStyleHsp" style=""></span>D&#58; ecocardiograma 3<span class="elsevierStyleHsp" style=""></span>D&#59; FEVE&#58; fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo&#59; GLS&#58; <span class="elsevierStyleItalic">global longitudinal strain&#59;</span> LIN&#58; limite inferior do normal&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Margarida Cruz, Joana Duarte&#8208;Rodrigues, Manuel Campelo"
            "autores" => array:3 [
              0 => array:2 [
                "nombre" => "Margarida"
                "apellidos" => "Cruz"
              ]
              1 => array:2 [
                "nombre" => "Joana"
                "apellidos" => "Duarte&#8208;Rodrigues"
              ]
              2 => array:2 [
                "nombre" => "Manuel"
                "apellidos" => "Campelo"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "pt"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2174204916300642"
          "doi" => "10.1016/j.repce.2015.12.020"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204916300642?idApp=UINPBA00004E"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255116000627?idApp=UINPBA00004E"
      "url" => "/08702551/0000003500000006/v1_201606140033/S0870255116000627/v1_201606140033/pt/main.assets"
    ]
  ]
  "itemSiguiente" => array:20 [
    "pii" => "S2174204916300290"
    "issn" => "21742049"
    "doi" => "10.1016/j.repce.2015.09.027"
    "estado" => "S300"
    "fechaPublicacion" => "2016-06-01"
    "aid" => "737"
    "copyright" => "Sociedade Portuguesa de Cardiologia"
    "documento" => "simple-article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "crp"
    "cita" => "Rev Port Cardiol. 2016;35:373&#46;e1-6"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4484
      "formatos" => array:3 [
        "EPUB" => 202
        "HTML" => 3586
        "PDF" => 696
      ]
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Case report</span>"
      "titulo" => "Left ventricular pseudoaneurysm &#8211; a challenging diagnosis"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "pt"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "373&#46;e1"
          "paginaFinal" => "373&#46;e6"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "pt" => array:1 [
          "titulo" => "Pseudoaneurisma ventricular esquerdo &#8211; um desafio diagn&#243;stico"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "pt" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0015"
          "etiqueta" => "Figure 3"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr3.jpeg"
              "Alto" => 737
              "Ancho" => 2500
              "Tamanyo" => 290630
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Repair of the pseudoaneurysm &#40;arrow&#41; by the modified Dor procedure&#59; &#40;B&#41; exclusion of the pseudoaneurysm with a Dacron patch &#40;arrowhead&#41; and Teflon strips&#59; &#40;C&#41; final result&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Mariana Faustino, Sara Ranchord&#225;s, Jo&#227;o Abecasis, Ant&#243;nio Freitas, Moradas Ferreira, Victor Gil, Carlos Morais, Jos&#233; Pedro Neves"
          "autores" => array:8 [
            0 => array:2 [
              "nombre" => "Mariana"
              "apellidos" => "Faustino"
            ]
            1 => array:2 [
              "nombre" => "Sara"
              "apellidos" => "Ranchord&#225;s"
            ]
            2 => array:2 [
              "nombre" => "Jo&#227;o"
              "apellidos" => "Abecasis"
            ]
            3 => array:2 [
              "nombre" => "Ant&#243;nio"
              "apellidos" => "Freitas"
            ]
            4 => array:2 [
              "nombre" => "Moradas"
              "apellidos" => "Ferreira"
            ]
            5 => array:2 [
              "nombre" => "Victor"
              "apellidos" => "Gil"
            ]
            6 => array:2 [
              "nombre" => "Carlos"
              "apellidos" => "Morais"
            ]
            7 => array:2 [
              "nombre" => "Jos&#233; Pedro"
              "apellidos" => "Neves"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "pt" => array:9 [
        "pii" => "S0870255115003169"
        "doi" => "10.1016/j.repc.2015.09.008"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "pt"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255115003169?idApp=UINPBA00004E"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204916300290?idApp=UINPBA00004E"
    "url" => "/21742049/0000003500000006/v2_201704050129/S2174204916300290/v2_201704050129/en/main.assets"
  ]
  "itemAnterior" => array:20 [
    "pii" => "S2174204916300320"
    "issn" => "21742049"
    "doi" => "10.1016/j.repce.2015.12.019"
    "estado" => "S300"
    "fechaPublicacion" => "2016-06-01"
    "aid" => "787"
    "copyright" => "Sociedade Portuguesa de Cardiologia"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "Rev Port Cardiol. 2016;35:351-8"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3063
      "formatos" => array:3 [
        "EPUB" => 171
        "HTML" => 2329
        "PDF" => 563
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
      "titulo" => "Cardiac device infection&#58; Review based on the experience of a single center"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "pt"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "351"
          "paginaFinal" => "358"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "pt" => array:1 [
          "titulo" => "Endocardite de dispositivos&#44; revis&#227;o com base na experi&#234;ncia de um centro"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "pt" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Andreia Fernandes, Miryan Cassandra, Joana Trigo, Jos&#233; Nascimento, Maria Carmo Cachulo, Rui Provid&#234;ncia, Marco Costa, Lino Gon&#231;alves"
          "autores" => array:8 [
            0 => array:2 [
              "nombre" => "Andreia"
              "apellidos" => "Fernandes"
            ]
            1 => array:2 [
              "nombre" => "Miryan"
              "apellidos" => "Cassandra"
            ]
            2 => array:2 [
              "nombre" => "Joana"
              "apellidos" => "Trigo"
            ]
            3 => array:2 [
              "nombre" => "Jos&#233;"
              "apellidos" => "Nascimento"
            ]
            4 => array:2 [
              "nombre" => "Maria"
              "apellidos" => "Carmo Cachulo"
            ]
            5 => array:2 [
              "nombre" => "Rui"
              "apellidos" => "Provid&#234;ncia"
            ]
            6 => array:2 [
              "nombre" => "Marco"
              "apellidos" => "Costa"
            ]
            7 => array:2 [
              "nombre" => "Lino"
              "apellidos" => "Gon&#231;alves"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "pt" => array:9 [
        "pii" => "S0870255116000639"
        "doi" => "10.1016/j.repc.2015.12.005"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "pt"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0870255116000639?idApp=UINPBA00004E"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204916300320?idApp=UINPBA00004E"
    "url" => "/21742049/0000003500000006/v2_201704050129/S2174204916300320/v2_201704050129/en/main.assets"
  ]
  "en" => array:20 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>"
    "titulo" => "Cardiotoxicity in anthracycline therapy&#58; Prevention strategies"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "359"
        "paginaFinal" => "371"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Margarida Cruz, Joana Duarte-Rodrigues, Manuel Campelo"
        "autores" => array:3 [
          0 => array:3 [
            "nombre" => "Margarida"
            "apellidos" => "Cruz"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Joana"
            "apellidos" => "Duarte-Rodrigues"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:4 [
            "nombre" => "Manuel"
            "apellidos" => "Campelo"
            "email" => array:1 [
              0 => "mcampelo&#64;hotmail&#46;com"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Faculdade de Medicina&#44; Universidade do Porto&#44; Porto&#44; Portugal"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servi&#231;o de Cardiologia&#44; Hospital de S&#46; Jo&#227;o&#44; Porto&#44; Portugal"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "pt" => array:1 [
        "titulo" => "Cardiotoxicidade na terap&#234;utica com antraciclinas&#58; estrat&#233;gias de preven&#231;&#227;o"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2375
            "Ancho" => 2417
            "Tamanyo" => 282865
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Initiation of a regimen potentially associated with anthracycline-induced cardiotoxicity&#46; 2DE&#58; two-dimensional echocardiography&#59; 3DE&#58; three-dimensional echocardiography&#59; GLS&#58; global longitudinal strain&#59; LLN&#58; lower limit of normal&#59; LVEF&#58; left ventricular ejection fraction&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">According to the World Health Organization&#44; cancer is the second leading cause of death worldwide&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> The considerable and ongoing advances in treatment have increased survival of cancer patients&#44; but the adverse effects of chemotherapy&#44; particularly on the heart&#44; are a significant cause of mortality and morbidity&#46; Mortality among cancer patients who develop anthracycline-induced cardiomyopathy is high &#40;over 60&#37; at two years&#41;&#44;<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> but prognosis can be improved by early detection and prevention&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Anthracyclines such as doxorubicin&#44; daunorubicin&#44; epirubicin&#44; mitoxantrone and idarubicin are the most commonly used chemotherapy drugs in cancer&#46; They are a known cause of cardiotoxicity &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#44; with acute or&#47;and subacute effects that can manifest as electrocardiographic changes&#44; ventricular and supraventricular arrhythmias&#44; cardiac conduction disturbances &#40;atrioventricular or branch block&#41;&#44; ventricular dysfunction&#44; rises in brain-type natriuretic peptide &#40;BNP&#44; a marker of increased preload and heart failure &#91;HF&#93;&#41;&#44; myocarditis and pericarditis&#44; and that may occur at any time between beginning of treatment and two weeks after the end of treatment&#46; These effects are relatively uncommon and most revert a week after treatment cessation&#46; Chronic cardiomyopathy is defined as early if it begins within a year of ending chemotherapy and late after that period&#46; In either case&#44; systolic or diastolic dysfunction are observed &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>&#41; that can progress to severe cardiomyopathy and may even lead to death&#46;<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> Although some studies have suggested that the risk of developing ventricular dysfunction and its severity can be predicted on the basis of acute myocardial injury&#44;<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> the relationship between acute and chronic toxicity is not fully understood&#46; Diagnosis of cardiac dysfunction induced by cancer therapy has been the subject of various studies&#44;<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3&#44;5</span></a> one of which<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> is considered the reference publication on the subject&#44; and is based on HF symptoms&#44; physical examination and parameters of left ventricular function&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">One proposed classification divides chemotherapy-induced cardiomyopathy into two types&#58; type I&#44; caused by anthracyclines&#44; which induce irreversible dose-dependent cardiac injury&#59; and type II&#44; caused by trastuzumab&#44; which is not related to the cumulative dose and is often reversible after treatment discontinuation&#46;<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> The second type will not be discussed in this review article&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">In this review the authors discuss strategies in patients being treated with anthracyclines in order to prevent or mitigate their main adverse effects on the heart&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Initial assessment</span><p id="par0025" class="elsevierStylePara elsevierViewall">In view of the cardiotoxicity of anthracyclines&#44; all patients referred for chemotherapy should undergo a cardiac assessment to establish their baseline cardiovascular characteristics&#44; which can then be used during the treatment regimen for purposes of comparison&#46; This assessment should include clinical history and physical examination&#44; electrocardiography to determine cardiac rhythm and detect signs of ischemia&#44; and cardiac imaging&#44; usually transthoracic echocardiography with complete Doppler study &#40;<a class="elsevierStyleCrossRefs" href="#tbl0015">Tables 3 and 4</a>&#41;&#46; When the echocardiogram is provides insufficient information&#44; cardiac magnetic resonance imaging &#40;CMRI&#41; is recommended&#46; Baseline troponin levels should also be measured for future comparisons&#46;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Monitoring during therapy</span><p id="par0030" class="elsevierStylePara elsevierViewall">It is important to monitor for signs and symptoms of cardiotoxicity during chemotherapy &#40;<a class="elsevierStyleCrossRef" href="#tbl0030">Table 5</a>&#41;&#46; The 12-lead electrocardiogram can be used routinely to screen for arrhythmias due to anthracycline-related cardiotoxicity&#44; while 24-hour Holter monitoring or an event recorder can be useful to investigate the etiology of syncope presumed to result from arrhythmia or advanced atrioventricular block&#46;<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> Cardiac function should be monitored by echocardiography in patients under anthracycline therapy&#46; Global longitudinal strain &#40;GLS&#41; as assessed by two-dimensional speckle tracking is a more sensitive predictor of HF than left ventricular ejection fraction &#40;LVEF&#41;&#44;<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> since during anthracycline therapy changes in GLS precede reduction in LVEF&#46;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> However&#44; in clinical practice&#44; fractional shortening and LVEF have been the most widely used parameters&#44;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> although fractional shortening is proving to be less reliable in this context&#46; These parameters&#44; being dependent on pre- and afterload&#44; are less sensitive for early detection of preclinical cardiac disease&#46; Various studies have suggested that assessment of diastolic function by Doppler echocardiography may enable early detection of anthracycline-induced cardiomyopathy&#46;<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10&#44;11</span></a> If LVEF is &#60;53&#37;&#44; GLS below the limit of normal &#40;<a class="elsevierStyleCrossRef" href="#tbl0035">Table 6</a>&#41;&#44; and&#47;or troponins are elevated&#44; a cardiology consultation should be considered&#44; with discussion between the cardiologist and oncologist of the risk&#47;benefit ratio of chemotherapy&#46;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> A fall in LVEF during anthracycline therapy is associated with increased risk for cardiac events&#44; and although a reduction in GLS of &#60;8&#37; compared to baseline appears not to be significant&#44; a reduction of &#62;15&#37; is likely to indicate cardiotoxicity&#46;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> The study should be repeated two to three weeks after the baseline study to confirm the diagnosis&#46; CMRI can detect subtle changes in the myocardium and increases in extracellular volume&#44; which suggest edema or diffuse fibrosis&#46; Although it is highly sensitive and reproducible for assessment of cardiac function and characterization of myocardial tissue&#44; CMRI has the disadvantages of limited availability and high cost&#46;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> Radionuclide angiography is reproducible and more easily available&#44; but exposes patients to ionizing radiation&#44; increasing their cumulative dose&#44; especially when serial studies are required&#44; and provides only limited information on diastolic function and valve morphology&#44; and so should not be the method of choice&#46;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> Endomyocardial biopsy has greater sensitivity and specificity for detection and monitoring of the adverse effects of anthracyclines&#44;<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> enabling visualization of loss of myofibrils&#44; vacuolization of cytoplasm&#44; dilatation of the sarcoplasmic reticulum&#44; increased numbers of lysosomes and mitochondrial swelling&#46;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a> However&#44; the invasive nature of the procedure limits its use in clinical practice&#46; Biomarkers have been validated in various studies&#59; they are specific not only in detecting cardiovascular injury but also in determining its extent and reversibility&#46; While troponin T and I are indicators of cardiomyocyte damage&#44; BNP and the N-terminal portion of pro-BNP &#40;NT-proBNP&#41; reflect increased myocardial stress&#46;<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">13&#44;14</span></a> According to the literature&#44; elevation of troponins is an early indicator of cardiotoxicity&#44; while BNP is less consistent&#46;</p><elsevierMultimedia ident="tbl0030"></elsevierMultimedia><elsevierMultimedia ident="tbl0035"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">If the dose of anthracyclines exceeds 240 mg&#47;m<span class="elsevierStyleSup">2</span>&#44; cardiac assessment should be repeated before administering further cycles &#40;<a class="elsevierStyleCrossRef" href="#fig0005">Figure 1</a>&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Prevention of cardiotoxicity</span><p id="par0040" class="elsevierStylePara elsevierViewall">Prevention of anthracycline-induced cardiotoxicity&#44; while maintaining the drugs&#8217; therapeutic effectiveness&#44; can be achieved by pharmacological and non-pharmacological means&#46;</p><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Non-pharmacological prevention</span><p id="par0045" class="elsevierStylePara elsevierViewall">Cardiovascular risk factors should be identified and treated appropriately as soon as cancer is diagnosed&#46; Patients should be encouraged to adopt a healthy lifestyle&#44; including a diet low in saturated fat and a maximum of 2&#46;5 g of sodium per day&#44; avoid toxic substances such as alcohol and tobacco&#44; and maintain their body mass index close to 25 kg&#47;m<span class="elsevierStyleSup">2</span>&#46; Exercise&#44; whether of low or high intensity&#44; during anthracycline therapy increases cardiovascular reserve<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> and studies in animal models have indicated that it may reduce the cardiotoxic effects of these agents&#46;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> Although exercise has shown promise in improving cardiopulmonary function in breast cancer survivors&#44;<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">17&#44;18</span></a> there have been no clinical trials in humans that confirm their cardioprotective role&#46; Another measure is to reduce or avoid the use of drugs that prolong QT interval&#44; particularly 5-hydroxytryptamine 3 antagonists &#40;frequently used to prevent adverse effects of chemotherapy including nausea and vomiting&#41; and antihistamines&#46;<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">19&#44;20</span></a> It is also important to minimize radiation exposure&#44; to correct electrolyte disturbances and to treat comorbidities &#40;<a class="elsevierStyleCrossRef" href="#tbl0040">Table 7</a>&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a></p><elsevierMultimedia ident="tbl0040"></elsevierMultimedia><p id="par0050" class="elsevierStylePara elsevierViewall">Decreasing the dose of anthracyclines is another way to reduce the incidence of left ventricular systolic dysfunction &#40;LVSD&#41;&#44; as shown by a study of patients taking 400&#44; 500 or 550 mg&#47;m<span class="elsevierStyleSup">2</span> of doxorubicin&#44; in which the incidence of congestive HF was 5&#37;&#44; 16&#37; and 26&#37; respectively&#46;<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> Although anthracyclines appear to be cardiotoxic independently of the dose administered&#44; several studies have shown that continuous infusion of lower doses for between 24 and 92 hours<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> can reduce the severity of cardiac injury&#44; and has been described as an effective way of doing so&#46;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> Prolonging infusion time reduces cardiotoxicity without compromising the effectiveness of chemotherapy&#44;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> but infusion lasting longer than 96 hours is associated with a high incidence of stomatitis&#46; The only case in which continuous infusion of doxorubicin appears to have no cardioprotective effect compared to rapid infusion is in children with acute lymphoblastic leukemia &#40;ALL&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a> Other clinical trials using endomyocardial biopsy to assess anthracycline-induced cardiac injury in different drug regimens concluded that continuous perfusion leads to far less significant damage than rapid intravenous administration&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a> These trials also showed that patients receiving continuous infusion had greater tolerance for higher cumulative doses of doxorubicin&#46; Although animal studies demonstrated that anthracycline levels in tumor tissue were the same however the drugs were administered &#40;continuous or rapid infusion&#41;&#44; this was not true of cardiac tissue&#44; in which rapid infusion led to higher concentrations and thus greater toxicity&#46;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Pharmacological prevention</span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Antioxidants</span><p id="par0055" class="elsevierStylePara elsevierViewall">Although antioxidants neutralize free radicals formed by anthracycline therapy and thus theoretically reduce or prevent cardiotoxicity&#44; clinical trials of N-acetylcysteine&#44; coenzyme Q&#44; L-carnitine&#44; phenethylamines&#44; amifostine and a combination of vitamins E and C and N-acetylcysteine did not show a cardioprotective effect&#46;<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">29</span></a> Erythropoietin and iloprost<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">30</span></a> have been shown to protect against the cardiotoxic effects of doxorubicin in vitro&#44; without affecting its anticancer effectiveness&#44; but their cardioprotective ability will have to be demonstrated in vivo&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Liposomal formulations</span><p id="par0060" class="elsevierStylePara elsevierViewall">One way to combat the adverse cardiac effects of anthracyclines is to change the formulation of the drugs such as encapsulating them in liposomes&#46;<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">31</span></a> Studies comparing unencapsulated and liposome-encapsulated doxorubicin found no difference in anti-tumor response rate&#44; overall survival or progression-free survival&#44; but the incidence of HF and LVSD was lower in patients treated with the liposomal formulation&#44; and this group also had a lower incidence of other adverse effects including neutropenia&#44; nausea&#44; vomiting and diarrhea&#46;<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">32</span></a> Due to their high cost&#44; these formulations are not widely used and the US Food and Drug Administration &#40;FDA&#41; has approved their use only for ovarian cancer&#44; AIDS-related Kaposi&#39;s sarcoma&#44; and patients with multiple myeloma who have not responded to a year of treatment with other drugs&#46;<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Dexrazoxane</span><p id="par0065" class="elsevierStylePara elsevierViewall">Administration of dexrazoxane concomitantly with anticancer regimens can have a cardioprotective effect&#44; preventing elevation of troponins and reducing the incidence of HF&#46;<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">34</span></a> Some authors attribute the cardioprotective effect of this iron chelator to its reduction of the quantity of intracellular iron&#44; which may decrease doxorubicin-induced free radical generation&#46;<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">34</span></a> However&#44; studies on other iron chelators have not demonstrated cardioprotection&#46;<a class="elsevierStyleCrossRefs" href="#bib0175"><span class="elsevierStyleSup">35&#44;36</span></a> It has also been suggested that dexrazoxane&#39;s cardioprotective effect is due not only to its antagonizing topoisomerase II cleavage complex formation&#44; but also to its induction of rapid degradation of topoisomerase II beta&#44; which suggests that this enzyme is involved in anthracycline-induced cardiotoxicity&#46;<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">37</span></a> A study of dexrazoxane in over 200 children with ALL showed that it reduced troponin T elevation in both sexes&#44;<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">38</span></a> and limited reduction of fractional shortening and maintained left ventricular thickness-to-dimension ratio at five years&#44; but only in girls&#46;<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">39</span></a> Recently three cases have been reported of adults undergoing chemotherapy combined with dexrazoxane for breast cancer who developed acute myeloid leukemia&#46; However&#44; two studies comparing dexrazoxane with placebo in children with ALL followed for five and 10 years showed no difference in the incidence of secondary malignancy&#46;<a class="elsevierStyleCrossRefs" href="#bib0200"><span class="elsevierStyleSup">40&#44;41</span></a> Nevertheless&#44; in view of its known adverse effects&#44; the FDA and the European Medicines Agency have restricted the use of dexrazoxane to adult patients with advanced or metastatic breast cancer who have already received a cumulative dose of doxorubicin of more than 300 mg&#47;m<span class="elsevierStyleSup">2</span> and who will benefit from additional anthracycline therapy&#46;<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">42</span></a></p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Beta-blockers</span><p id="par0070" class="elsevierStylePara elsevierViewall">The cardioprotection afforded by beta-blockers &#40;BBs&#41; appears to derive from their antioxidant and anti-apoptotic properties&#46; One BB&#44; carvedilol&#44; has shown particular promise in reducing the incidence of anthracycline-induced cardiomyopathy and preserving systolic and diastolic function&#46;<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">43</span></a> In children&#44; carvedilol limited troponin I elevation and improved both fractional shortening and peak global systolic strain&#46;<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">44</span></a> According to some studies&#44; BBs and angiotensin-converting enzyme &#40;ACE&#41; inhibitors &#40;see below&#41; can prevent the remodeling associated with HF by reducing adrenergic response&#46;<a class="elsevierStyleCrossRefs" href="#bib0225"><span class="elsevierStyleSup">45&#44;46</span></a> However&#44; no cardioprotective effects have been seen with either metoprolol or enalapril&#46;<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">47</span></a></p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers</span><p id="par0075" class="elsevierStylePara elsevierViewall">ACE inhibitors and angiotensin receptor blockers &#40;ARBs&#41; show cardioprotective properties&#44; possibly by reducing oxidative stress&#44; left ventricular remodeling&#44; and apoptosis&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">48</span></a> When administered for at least two years after discontinuation of chemotherapy in children with anthracycline-induced LVSD&#44; enalapril showed no benefit in terms of reducing left ventricular end-systolic wall stress or preserving fractional shortening&#46;<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">49</span></a> By contrast&#44; in adults treated with high-dose anthracyclines&#44; enalapril prevented HF and worsening of parameters of cardiac function such as LVEF&#46;<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">50</span></a> Studies in angiotensin II type I receptor knockout mice showed that doxorubicin did not have a cardiotoxic effect in these animals and that the administration of ARBs can prevent daunorobucin-induced cardiomyopathy&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">48</span></a> Although to our knowledge there have been only two randomized trials on ARBs in chemotherapy patients&#44; valsartan was shown to prevent acute prolongation of corrected QT&#44; left ventricular diastolic dilatation and elevation of BNP during one week of chemotherapy&#44; although with no effect on LVEF&#44;<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">51</span></a> and telmisartan prevented reduction in peak strain rate during high-dose anthracycline therapy&#46;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">52</span></a> Further studies are required with longer follow-up to confirm these effects&#46;</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Statins</span><p id="par0080" class="elsevierStylePara elsevierViewall">Statins have antioxidant and anti-inflammatory properties&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">53</span></a> Studies in animal models demonstrate that fluvastatin mitigates anthracycline-induced cardiotoxicity&#44; reducing oxidative stress and enhancing the expression of the antioxidant enzyme mitochondrial superoxide dismutase 2&#44; resulting in reduced cardiac inflammation&#46;<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">53</span></a> In one clinical trial assessing the effect of continuous statin treatment in patients with breast cancer receiving anthracycline-based chemotherapy&#44; patients receiving statins had a lower incidence of HF&#46;<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a> In another study in patients with previously normal LVEF undergoing anthracycline chemotherapy&#44; LVEF was unchanged at six months in those treated with atorvastatin&#44; compared to a fall of 8&#37; in the control group&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">55</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">Finally&#44; it should be emphasized that there is as yet no solid evidence for the effectiveness of pharmacological prevention of anthracycline-induced cardiomyopathy&#44; and so the main preventive strategy remains thorough prior cardiovascular assessment of patients and appropriate monitoring&#44; selection and adjustment of chemotherapy dosages&#46;</p></span></span></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Treatment of heart failure</span><p id="par0090" class="elsevierStylePara elsevierViewall">After the development of signs or symptoms of HF or a reduction in LVEF due to chemotherapy-related cardiotoxicity&#44; treatment should be based on the current guidelines&#46;<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">56</span></a> Although selection of the best therapy is obviously important&#44; one study has shown that the main factor determining successful treatment is the time between the end of chemotherapy and the start of HF therapy&#44; since if this is longer than six months&#44; LVEF is unlikely to recover completely&#46;<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">57</span></a></p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Prospects for the future</span><p id="par0095" class="elsevierStylePara elsevierViewall">Several clinical trials are currently under way aiming to assess various therapeutic strategies&#44; pharmacological and non-pharmacological&#44; for the prevention of anthracycline-induced cardiomyopathy &#40;<a class="elsevierStyleCrossRef" href="#tbl0045">Table 8</a>&#41;&#46; It will be some years before the results are known&#44; and there is still a pressing need for evidence-based guidelines for the assessment and clinical monitoring of these patients&#46;</p><elsevierMultimedia ident="tbl0045"></elsevierMultimedia></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Conclusion</span><p id="par0100" class="elsevierStylePara elsevierViewall">The longer survival of patients undergoing anticancer therapy and the consequent increase in the incidence of anthracycline-induced cardiomyopathy mean that it is necessary to investigate and determine the precise mechanisms leading to adverse cardiac effects&#44; in order to prevent them&#46; Further research will enable specific and validated prevention plans to be established&#46;</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Conflicts of interest</span><p id="par0105" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres824756"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec821215"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres824757"
          "titulo" => "Resumo"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec821214"
          "titulo" => "Palavras-chave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Initial assessment"
          "secciones" => array:1 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Monitoring during therapy"
            ]
          ]
        ]
        6 => array:3 [
          "identificador" => "sec0020"
          "titulo" => "Prevention of cardiotoxicity"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Non-pharmacological prevention"
            ]
            1 => array:3 [
              "identificador" => "sec0030"
              "titulo" => "Pharmacological prevention"
              "secciones" => array:6 [
                0 => array:2 [
                  "identificador" => "sec0035"
                  "titulo" => "Antioxidants"
                ]
                1 => array:2 [
                  "identificador" => "sec0040"
                  "titulo" => "Liposomal formulations"
                ]
                2 => array:2 [
                  "identificador" => "sec0045"
                  "titulo" => "Dexrazoxane"
                ]
                3 => array:2 [
                  "identificador" => "sec0050"
                  "titulo" => "Beta-blockers"
                ]
                4 => array:2 [
                  "identificador" => "sec0055"
                  "titulo" => "Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers"
                ]
                5 => array:2 [
                  "identificador" => "sec0060"
                  "titulo" => "Statins"
                ]
              ]
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0065"
          "titulo" => "Treatment of heart failure"
        ]
        8 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Prospects for the future"
        ]
        9 => array:2 [
          "identificador" => "sec0075"
          "titulo" => "Conclusion"
        ]
        10 => array:2 [
          "identificador" => "sec0080"
          "titulo" => "Conflicts of interest"
        ]
        11 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2015-07-27"
    "fechaAceptado" => "2015-12-20"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec821215"
          "palabras" => array:4 [
            0 => "Anthracyclines"
            1 => "Cardiotoxicity"
            2 => "Prevention"
            3 => "Chemotherapy"
          ]
        ]
      ]
      "pt" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palavras-chave"
          "identificador" => "xpalclavsec821214"
          "palabras" => array:4 [
            0 => "Antraciclinas"
            1 => "Cardiotoxicidade"
            2 => "Preven&#231;&#227;o"
            3 => "Quimioterapia"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The increasing use of anthracyclines&#44; together with the longer survival of cancer patients&#44; means the toxic effects of these drugs need to be monitored&#46; In order to detect&#44; prevent or mitigate anthracycline-induced cardiomyopathy&#44; it is essential that all patients undergo a rigorous initial cardiovascular assessment&#44; followed by close monitoring&#46; Several clinical trials have shown the cardioprotective effect of non-pharmacological measures such as exercise&#44; healthy lifestyles&#44; control of risk factors and treatment of comorbidities&#59; a cardioprotective effect has also been observed with pharmacological measures such as beta-blockers&#44; angiotensin-converting enzyme inhibitors&#44; angiotensin receptor antagonists&#44; statins&#44; dexrazoxane and liposomal formulations&#46; However&#44; there are currently no guidelines for managing prevention in these patients&#46; In this review the authors discuss the state of the art of the assessment&#44; monitoring&#44; and&#44; above all&#44; the prevention of anthracycline-induced cardiotoxicity&#46;</p></span>"
      ]
      "pt" => array:2 [
        "titulo" => "Resumo"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">O crescente uso de antraciclinas&#44; aliado ao aumento da sobrevida dos doentes oncol&#243;gicos&#44; motiva a necessidade de monitorizar os efeitos t&#243;xicos destes f&#225;rmacos&#46; Para que a sua cardiotoxicidade possa ser detetada&#44; prevenida ou atenuada&#44; torna-se essencial que todos os doentes sejam&#44; do ponto de vista cardiovascular&#44; submetidos a uma rigorosa avalia&#231;&#227;o inicial e a um estreito acompanhamento&#46; Diversos ensaios cl&#237;nicos comprovaram o efeito cardioprotetor produzido por medidas n&#227;o farmacol&#243;gicas como o exerc&#237;cio f&#237;sico&#44; a ado&#231;&#227;o de um estilo de vida saud&#225;vel&#44; o controlo de fatores de risco e o tratamento de comorbilidades&#59; foi tamb&#233;m verificado um efeito cardioprotetor com estrat&#233;gias farmacol&#243;gicas como o uso de bloqueadores-beta&#44; inibidores da enzima de convers&#227;o da angiotensina&#44; antagonistas do recetor da angiotensina&#44; estatinas&#44; dexrazoxane ou derivados lisossomais&#46; No entanto&#44; atualmente n&#227;o existe qualquer diretriz cient&#237;fica que oriente as estrat&#233;gias de preven&#231;&#227;o nestes doentes&#46; Com esta revis&#227;o propomo-nos abordar o estado da arte relativo &#224; avalia&#231;&#227;o&#44; monitoriza&#231;&#227;o e&#44; principalmente&#44; &#224; preven&#231;&#227;o da cardiotoxicidade provocada pelas antraciclinas&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Please cite this article as&#58; Cruz M&#44; Duarte-Rodrigues J&#44; Campelo M&#46; Cardiotoxicidade na terap&#234;utica com antraciclinas&#58; estrat&#233;gias de preven&#231;&#227;o&#46; Rev Port Cardiol&#46; 2016&#59;35&#58;359&#8211;371&#46;</p>"
      ]
    ]
    "multimedia" => array:9 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2375
            "Ancho" => 2417
            "Tamanyo" => 282865
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Initiation of a regimen potentially associated with anthracycline-induced cardiotoxicity&#46; 2DE&#58; two-dimensional echocardiography&#59; 3DE&#58; three-dimensional echocardiography&#59; GLS&#58; global longitudinal strain&#59; LLN&#58; lower limit of normal&#59; LVEF&#58; left ventricular ejection fraction&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">AV&#58; atrioventricular&#46;</p><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Adapted from <a class="elsevierStyleCrossRefs" href="#bib0120"><span class="elsevierStyleSup">24&#44;58&#44;59</span></a>&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Mechanisms of action&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Mechanisms of cardiotoxicity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Anthracycline&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Therapeutic use&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Cardiotoxicity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " rowspan="5" align="left" valign="middle">The formation of a DNA complex by conjugation of flat rings with nucleotides inhibits DNA and RNA and protein synthesis&#46; This triggers DNA cleavage by topoisomerase II&#44; resulting in cytotoxicity&#46;<br><br>Anthracyclines inhibit helicase&#44; preventing enzymatic cleavage of the DNA double strand and thus interfering with replication and transcription&#46;<br><br><br>They cause redox reactions through formation of cytotoxic free radicals&#46;</td><td class="td" title="table-entry  " rowspan="5" align="left" valign="middle">Main mechanisms&#58;<br>- topoisomerase II beta-mediated DNA damage<br>- lipid peroxidation<br>- oxidative stress<br>- apoptosis and necrosis of cardiac cells<br><br>Impaired synthesis of DNA&#44; RNA and proteins and of transcription factors involved in regulation of genes specific to the heart&#46;<br><br>Negative balance of sarcomeric proteins in cardiac cells caused by reduced protein expression and increased myofilament degradation&#46; Combination therapy exacerbates myofilament loss&#46;<br>Mitochondrial DNA damage and changes in mitochondrial bioenergetics&#46;<br><br>Disruption of the dynamic regulation of cardiac function&#44; altering adrenergic and adenylyl cyclase activity and calcium homeostasis&#46;</td><td class="td" title="table-entry  " align="left" valign="middle">Doxorubicin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="middle">Advanced stomach cancer<br>Bladder cancer<br>Breast cancer<br>Ovarian cancer<br>Small cell lung cancer<br>Thyroid cancer<br>Hodgkin disease<br>Acute leukemia<br>Non-Hodgkin lymphoma<br>Neuroblastoma<br>Sarcoma<br>Wilms tumor&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Acute&#58;<br><span class="elsevierStyleHsp" style=""></span>Hypotension<br><span class="elsevierStyleHsp" style=""></span>Arrhythmias<br><span class="elsevierStyleHsp" style=""></span>Tachycardia<br><span class="elsevierStyleHsp" style=""></span>Thromboembolism<br>Subacute&#58;<br><span class="elsevierStyleHsp" style=""></span>Pericarditis<br><span class="elsevierStyleHsp" style=""></span>Myocarditis<br>Chronic&#58;<br><span class="elsevierStyleHsp" style=""></span>Dilated cardiomyopathy<br><span class="elsevierStyleHsp" style=""></span>Contractile dysfunction<br><span class="elsevierStyleHsp" style=""></span>Congestive heart failure&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="middle">Daunorubicin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="middle">Acute lymphoblastic leukemia<br>Acute myeloid leukemia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Acute&#58;<br><span class="elsevierStyleHsp" style=""></span>Sinus tachycardia<br><span class="elsevierStyleHsp" style=""></span>Tachyarrhythmias<br><span class="elsevierStyleHsp" style=""></span>Ventricular extrasystoles<br><span class="elsevierStyleHsp" style=""></span>AV block<br>Chronic&#58;<br><span class="elsevierStyleHsp" style=""></span>Dilated cardiomyopathy<br><span class="elsevierStyleHsp" style=""></span>Contractile dysfunction<br><span class="elsevierStyleHsp" style=""></span>Congestive heart failure&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="middle">Epirubicin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="middle">Advanced ovarian cancer<br>Stomach cancer<br>Breast cancer<br>Lung cancer&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Acute&#58;<br><span class="elsevierStyleHsp" style=""></span>Ventricular tachycardia<br><span class="elsevierStyleHsp" style=""></span>AV block<br><span class="elsevierStyleHsp" style=""></span>Bundle branch block<br><span class="elsevierStyleHsp" style=""></span>Bradycardia<br><span class="elsevierStyleHsp" style=""></span>Thromboembolism<br>Chronic&#58;<br><span class="elsevierStyleHsp" style=""></span>Dilated cardiomyopathy<br><span class="elsevierStyleHsp" style=""></span>Contractile dysfunction<br><span class="elsevierStyleHsp" style=""></span>Congestive heart failure&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="middle">Idarubicin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="middle">Acute lymphocytic leukemia<br>Acute myeloid leukemia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Acute&#58;<br><span class="elsevierStyleHsp" style=""></span>Arrhythmias<br><span class="elsevierStyleHsp" style=""></span>Atrial fibrillation<br><span class="elsevierStyleHsp" style=""></span>Myocardial infarction<br><span class="elsevierStyleHsp" style=""></span>Thromboembolism<br>Chronic&#58;<br><span class="elsevierStyleHsp" style=""></span>Dilated cardiomyopathy<br><span class="elsevierStyleHsp" style=""></span>Contractile dysfunction<br><span class="elsevierStyleHsp" style=""></span>Congestive heart failure&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="middle">Mitoxantrone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="middle">Advanced breast cancer<br>Acute myeloid leukemia in adults<br>Non-Hodgkin lymphoma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Acute&#58;<br><span class="elsevierStyleHsp" style=""></span>Arrhythmias<br><span class="elsevierStyleHsp" style=""></span>Myocarditis<br><span class="elsevierStyleHsp" style=""></span>Hypertension<br><span class="elsevierStyleHsp" style=""></span>Myocardial ischemia<br>Chronic&#58;<br><span class="elsevierStyleHsp" style=""></span>Dilated cardiomyopathy<br><span class="elsevierStyleHsp" style=""></span>Contractile dysfunction<br><span class="elsevierStyleHsp" style=""></span>Congestive heart failure&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1386611.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Cardiotoxicity&#44; pharmacokinetics and therapeutic use of anthracyclines&#46;</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Table 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">CHF&#58; congestive heart failure&#59; LVEF&#58; left ventricular ejection fraction&#46;</p><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Adapted from <a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3&#44;60</span></a>&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Any one of the criteria is sufficient to confirm a diagnosis of cardiac dysfunction&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Cardiomyopathy characterized by a decrease in cardiac LVEF that is either global or more severe in the septum&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Symptoms of CHF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Detection of S3 gallop&#44; tachycardia&#44; or both&#59;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Decline in LVEF of at least 5&#37; to less than 55&#37; with accompanying signs or symptoms of CHF&#44; or a decline in LVEF of at least 10&#37; to below 55&#37; without accompanying signs or symptoms&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1386613.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Criteria to confirm or revise a preliminary diagnosis of chemotherapy-induced cardiac dysfunction&#44; according to the Cardiac Review and Evaluation Committee&#46;</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Table 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Adapted from <a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a>&#46;</p><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">2D&#58; two-dimensional&#59; 3D&#58; three-dimensional&#59; ASE&#47;EAE&#58; American Society of Echocardiography&#47;European Association of Echocardiography&#59; BP&#58; blood pressure&#59; GLS&#58; global longitudinal strain&#59; HR&#58; heart rate&#59; IAC-Echo&#58; Intersocietal Accreditation Commission Echocardiography&#59; IV&#58; intravenous&#59; LV&#58; left ventricular&#59; LVEF&#58; left ventricular ejection fraction&#59; MAPSE&#58; mitral annular plane systolic excursion&#59; RV&#58; right ventricle&#59; TAPSE&#58; tricuspid annular plane systolic excursion&#59; VTI&#58; velocity-time integral&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Standard transthoracic echocardiography</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; In accordance with ASE&#47;EAE guidelines and IAC-Echo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">2D strain imaging acquisition</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Apical 3-&#44; 4-&#44; and 2-chamber views&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Acquire &#8805;3 cardiac cycles&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Images obtained simultaneously maintaining the same 2D frame rate and imaging depth&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Frame rate between 40 and 90 frames&#47;s or &#8805;40&#37; of HR</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Aortic VTI &#40;aortic ejection time&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">2D strain imaging analysis</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Quantify segmental and global longitudinal strain&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Display the segmental strain curves from apical views in a quad format&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Display the global strain in a bull&#39;s-eye plot&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">2D strain imaging pitfalls</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Ectopy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Breathing translation&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">3D imaging acquisition</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Apical 4-chamber full volume to assess LV volumes and to calculate LVEF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Single and multiple beats optimizing spatial and temporal resolution&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Reporting</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Timing of echocardiography with respect to the IV infusion &#40;number of days before or after&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Vital signs &#40;BP&#44; HR&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; 3D LVEF&#47;2D biplane Simpson method&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; GLS &#40;echocardiography machine&#44; software&#44; and version used&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; In the absence of GLS&#44; measurement of medial and lateral s&#8242; and MAPSE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; RV&#58; TAPSE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1386612.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Recommended cardio-oncology echocardiogram protocol&#46;</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0025"
        "etiqueta" => "Table 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Adapted from <a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a>&#46;</p><p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">2DE&#58; two-dimensional echocardiography&#59; 3DE&#58; three-dimensional echocardiography&#59; ASE&#47;EAE&#58; American Society of Echocardiography&#47;European Association of Echocardiography&#59; GLS&#58; global longitudinal strain&#59; LV&#58; left ventricular&#59; LVEF&#58; left ventricular ejection fraction&#59; STE&#58; speckle-tracking echocardiography&#59; TDI&#58; tissue Doppler imaging&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">LV systolic function</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Echocardiography is the method of choice for the assessment of patients before&#44; during and after cancer therapy&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Accurate calculation of LVEF should be done with the best method available in the echocardiography laboratory &#40;ideally 3DE&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; When using 2DE&#44; the modified biplane Simpson technique is the method of choice&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; LVEF should be combined with the calculation of wall motion score index&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; In the absence of GLS by STE&#44; quantification of LV longitudinal function using MAPSE and&#47;or peak systolic velocity &#40;s&#8242;&#41; of the mitral annulus by pulsed-wave TDI is recommended&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; LVEF assessed by 2DE often fails to detect small changes in LV contractility&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Diastolic function</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>&#8226; Although diastolic parameters have not been found to be prognostic of anthracycline-induced cardiomyopathy&#44; a conventional assessment of LV diastolic function&#44; including grading of diastolic function and non-invasive estimation of LV filling pressures&#44; should be added to the assessment of LV systolic function&#44; according to ASE&#47;EAE recommendations for the evaluation of LV diastolic function with echocardiography&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1386610.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Echocardiographical assessment of systolic and diastolic function in the cancer patient&#46;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0030"
        "etiqueta" => "Table 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at5"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Adapted from <a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5&#44;12&#44;61</span></a>&#46;</p><p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">2D&#58; two-dimensional&#59; CAD&#58; coronary artery disease&#59; CV&#58; cardiovascular&#59; ECG&#58; electrocardiography&#59; GFR&#58; glomerular filtration rate&#59; GLS&#58; global longitudinal strain&#59; HF&#58; heart failure&#59; LV&#58; left ventricular&#59; LVEF&#58; left ventricular ejection fraction&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Diagnostic exam&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Advantages&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Disadvantages&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Electrocardiography&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Non-invasive<br>Low cost<br>Measures QT interval&#44; prolongation of which is a known marker of cardiotoxicity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Does not measure LVEF<br>Intra- and inter-observer variability in measurement of QT interval&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Doppler echocardiography&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Non-invasive<br>Low cost<br>Assessment of functional and morphological diastolic &#40;pulmonary venous flow&#44; E&#47;A ratio&#44; isovolumic relaxation time&#41; and systolic &#40;wall thickening during systole&#44; LVEF&#44; fractional shortening&#41; parameters&#44; valve structure and pericardium&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Intra- and inter-observer variability<br>Measurement of LVEF subject to variability and dependent on image quality<br>Doubtful predictive value for early detection of subclinical lesions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Tissue Doppler imaging&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Excellent temporal resolution<br>Early detection of subclinical lesions &#40;in combination with markers of inflammation and oxidative stress&#41;<br>Functional assessment of filling pressures &#40;E&#47;e&#8242; ratio&#41;&#44; velocities&#44; strain and strain rate of ventricular walls in systole and diastole<br>Detection of isolated diastolic dysfunction&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">More time-consuming analysis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">2D strain&#47;speckle tracking and GLS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Superior to LVEF for predicting cardiovascular mortality in the general population<br>Better risk stratification in HF patients<br>Able to recognize early LV dysfunction in patients undergoing cardiotoxic therapy<br>Reproducible when performed by an experienced operator&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Heavily dependent on image quality of 2D echocardiography<br>Lack of long-term clinical trials assessing the ability of GLS to predict persistent falls in LVEF or symptomatic HF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Stress echocardiography&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Assessment of myocardial contractile reserve&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Semi-invasive<br>Controversial and limited data on early detection of cardiotoxicity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Radionuclide angiography&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">High reproducibility<br>Low intra- and inter-observer variability<br>Validated for measurement of LVEF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ionizing radiation<br>Low spatial and temporal resolution<br>Underestimates ventricular volumes<br>Underestimates LVEF in small ventricles &#40;women and children&#41;<br>Does not assess valve function<br>Little information on diastolic function<br>Limited predictive value for early detection of subclinical lesions and changes in LVEF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Magnetic resonance imaging&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Reproducible<br>No ionizing radiation<br>Assessment of myocardial perfusion and function and pericardium&#44; and detection of myocardial masses<br>Useful in patients with poor echocardiographic image quality<br>Gold standard for calculation of LV volumes and of LVEF<br>T2 sequences&#58; detects segmental or global changes in myocardial water content resulting from inflammation or microvascular or myocyte damage<br>T1 sequences&#58; provides information on myocardial lesions and fibrosis&#59; with gadolinium contrast&#44; detects histopathological alterations including intracellular vacuolization&#44; enabling prediction of subsequent decrease in LVEF<br>Late enhancement&#58; detection of myocardial fibrosis associated with poor prognosis in patients with CAD&#44; hypertrophic cardiomyopathy and infiltrative disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">High cost<br>Limited availability<br>Contraindicated in patients with devices incompatible with magnetic resonance &#40;pacemakers&#44; cardiac resynchronization devices and implantable cardioverter-defibrillators&#41;<br>Risk of contrast nephrotoxicity in patients with renal failure &#40;GFR &#60;30 ml&#47;min&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Computed tomography&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">High-resolution image<br>Identifies pericardial calcification or thickening in patients undergoing radiotherapy or surgery<br>Visualizes and assesses calcification of the coronary arteries&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ionizing radiation<br>Documented coronary calcification prior to anticancer therapy is not predictive of CV risk in patients undergoing anthracycline chemotherapy<br>Little used for detection and monitoring of subclinical changes in cardiac function&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Scintigraphy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Non-invasive<br>Functional and structural assessment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ionizing radiation<br>Limited availability<br>Low temporal resolution<br>Limited data&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Biomarkers&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Non-invasive<br>Low inter-observer variability<br>Assessment of CV function and potential signs of cardiac damage<br>Promising for early detection of myocardial injury&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Undetermined predictive value&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Endomyocardial biopsy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Detects histological evidence of cardiac damage&#44; including loss of myofibrils&#44; vacuolization of cytoplasm&#44; dilatation of the sarcoplasmic reticulum&#44; increased numbers of lysosomes and mitochondrial swelling&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Invasive<br>Histological interpretation requires specialist knowledge<br>No functional information<br>Results limited by quantity and quality of biopsy sample&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Assessment of endothelial damage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Alternate parameters of cardiotoxicity such as cytokines&#44; adhesion molecules and carotid artery intima-media thickness&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Undetermined predictive value&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Genetic analysis&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Minimally invasive<br>Assesses individual susceptibility to cardiotoxicity&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Undetermined predictive value&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1386609.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Advantages and disadvantages of diagnostic exams in the assessment of anthracycline-induced cardiotoxicity&#46;</p>"
        ]
      ]
      6 => array:8 [
        "identificador" => "tbl0035"
        "etiqueta" => "Table 6"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at6"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0105" class="elsevierStyleSimplePara elsevierViewall">V1&#58; Vivid 7 or Vivid E9 &#40;GE Healthcare&#41;&#59; V2&#58; iE33 &#40;Philips Medical Systems&#41;&#59; V3&#58; Artida or Apilo &#40;Toshiba Medical Systems&#41;&#46;</p><p id="spar0110" class="elsevierStyleSimplePara elsevierViewall">Adapted from <a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">62</span></a>&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " colspan="7" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Age &#40;years&#41;</th></tr><tr title="table-row"><th class="td" title="table-head  " align="" valign="top" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">0-19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">20-29&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">30-39&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">40-49&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">50-59&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">&#8805;65&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">p&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">V1</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Overall&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-22&#46;1&#177;2&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-21&#46;2&#177;1&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-21&#46;1&#177;2&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-21&#46;4&#177;2&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-21&#46;0&#177;2&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;3&#177;1&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;0218&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Male&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-21&#46;7&#177;3&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;9&#177;1&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;6&#177;1&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;9&#177;1&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-21&#46;0&#177;1&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-19&#46;7&#177;1&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;1982&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Female&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-22&#46;4&#177;1&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-22&#46;3&#177;1&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-22&#46;8&#177;1&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-22&#46;6&#177;2&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-23&#46;3&#177;1&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;9&#177;2&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;0348&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>p &#40;male vs&#46; female&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;4292&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;0316&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">&#60;0&#46;0001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;0178&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;0029&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;1381&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">V2</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Overall&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-19&#46;9&#177;2&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-19&#46;0&#177;2&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-19&#46;5&#177;2&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-18&#46;2&#177;2&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-17&#46;6&#177;2&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-16&#46;7&#177;2&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">&#60;0&#46;0001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Male&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-19&#46;4&#177;2&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-18&#46;8&#177;2&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-19&#46;1&#177;2&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-17&#46;9&#177;2&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-16&#46;9&#177;2&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-15&#46;8&#177;1&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;0019&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Female&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;5&#177;2&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;6&#177;2&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;2&#177;2&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-19&#46;3&#177;0&#46;9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;4&#177;1&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-17&#46;3&#177;2&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;0002&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>p &#40;male vs&#46; female&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;1349&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;0248&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;1083&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;4316&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;0294&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;0928&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="8" align="left" valign="top"><span class="elsevierStyleItalic">V3</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Overall&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-21&#46;4&#177;1&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;2&#177;2&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;4&#177;2&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-19&#46;4&#177;2&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-18&#46;5&#177;2&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-17&#46;8&#177;2&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">&#60;0&#46;0001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Male&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-21&#46;6&#177;2&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;2&#177;2&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;4&#177;2&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-19&#46;8&#177;2&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-18&#46;7&#177;2&#46;6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-16&#46;3&#177;3&#46;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">&#60;0&#46;0001&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Female&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-21&#46;2&#177;1&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;2&#177;2&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-20&#46;4&#177;2&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-18&#46;7&#177;1&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-18&#46;3&#177;2&#46;8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">-18&#46;6&#177;2&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;0141&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>p &#40;male vs&#46; female&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;6076&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;9787&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;9201&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;1415&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;7374&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">0&#46;0668&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1386614.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">Normal values of global longitudinal strain by vendor of scanner&#44; gender&#44; and age&#46;</p>"
        ]
      ]
      7 => array:8 [
        "identificador" => "tbl0040"
        "etiqueta" => "Table 7"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at7"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0120" class="elsevierStyleSimplePara elsevierViewall">CV&#58; cardiovascular&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Cumulative doses exceeding&#58;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " colspan="2" align="left" valign="top">Recommended maximum &#40;mg&#47;m<span class="elsevierStyleSup">2</span>&#41;<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&#58;</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Doxorubicin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">400-550&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Daunorubicin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">550-800&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Epirubicin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">900-1000&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Idarubicin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">150-225&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Mitoxantrone&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">100-140&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Pre-existing CV disease&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " colspan="2" align="left" valign="top">Diabetes</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " colspan="2" align="left" valign="top">Coronary artery disease</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " colspan="2" align="left" valign="top">Peripheral vascular disease</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " colspan="2" align="left" valign="top">Hypertension</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top">Genetic predisposition&#58; female gender&#44; black race</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top">Previous or concomitant mediastinal radiation</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top">Intravenous bolus administration</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top">Combination with other agents including cyclophosphamide&#44; trastuzumab or paclitaxel</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top">Length of time since end of chemotherapy</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top">Electrolyte disturbances&#58; hypocalcemia&#44; hypomagnesemia</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top">Hemochromatosis &#40;C282Y mutation&#41;</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top">Hyperthermia</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="3" align="left" valign="top">Liver disease</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1386615.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Patients aged over 65 and children may develop cardiotoxicity with lower cumulative doses&#46;</p> <p class="elsevierStyleNotepara" id="npar0010">Adapted from <a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12&#44;24</span></a>&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0115" class="elsevierStyleSimplePara elsevierViewall">Risk factors for anthracycline-induced cardiotoxicity&#46;</p>"
        ]
      ]
      8 => array:8 [
        "identificador" => "tbl0045"
        "etiqueta" => "Table 8"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at8"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0135" class="elsevierStyleSimplePara elsevierViewall">CT&#58; computed tomography&#59; GLS&#58; global longitudinal strain&#59; LVDF&#58; left ventricular diastolic function&#59; LVEF&#58; left ventricular ejection fraction&#59; LVSD&#58; left ventricular systolic dysfunction&#59; MRI&#58; magnetic resonance imaging&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Lead author and ClinicalTrials&#46;gov no&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Type of trial&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Condition&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Chemotherapy agent&#40;s&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Intervention&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">No&#46; of patients&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Follow-up&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Primary outcome measure&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Planned trial conclusion&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Mavrudis D<br><span class="elsevierStyleInterRef" id="intr0005" href="ctgov:NCT01120171">NCT01120171</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Randomized&#44; phase 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Breast cancer&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Anthracyclines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Cyclophosphamide vs&#46; liposome-encapsulated doxorubicin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">48&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Overall response rate by CT or MRI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">May 2015&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Campbell K<br><span class="elsevierStyleInterRef" id="intr0010" href="ctgov:NCT02006979">NCT02006979</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Single blind&#44; phase 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Breast cancer&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Anthracyclines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">An acute bout of exercise performed 24 hours prior to every anthracycline infusion&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">24&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1 year&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">GLS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">December 2015&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Cipolla C<br><span class="elsevierStyleInterRef" id="intr0015" href="ctgov:NCT01968200">NCT01968200</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Randomized&#44; phase 3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Cancer&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Anthracyclines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Enalapril after appearance of cardiac injury vs&#46; enalapril concomitantly to chemotherapy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">268&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Up to one year after completion of chemotherapy&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Cardiac troponin levels&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">July 2016&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Virani S<br><span class="elsevierStyleInterRef" id="intr0020" href="ctgov:NCT01708798">NCT01708798</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Double blind&#44; phase 2&#44; 3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Breast cancer&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Anthracyclines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Eplerenone vs&#46; placebo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">78&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6 months&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Change in LVDF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">May 2015&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Bocchi E<br><span class="elsevierStyleInterRef" id="intr0025" href="ctgov:NCT01724450">NCT01724450</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Double blind&#44; phase 3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Breast cancer&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Anthracyclines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Carvedilol vs&#46; placebo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">200&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">LVSD &#40;10&#37; reduction in LVEF&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">October 2016&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Livi L<br><span class="elsevierStyleInterRef" id="intr0030" href="ctgov:NCT02236806">NCT02236806</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Single blind&#44; phase 3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Breast cancer&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Anthracyclines and trastuzumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Bisoprolol vs&#46; ramipril&#44; bisoprolol vs&#46; placebo&#44; ramipril vs&#46; placebo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">480&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1 year&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">LVEF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">November 2017&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Smith K<br><span class="elsevierStyleInterRef" id="intr0035" href="ctgov:NCT02096588">NCT02096588</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Randomized&#44; phase 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Breast cancer&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Anthracyclines&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Simvastatin&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="char" valign="top">90&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5 years&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">GLS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">April 2021&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab1386608.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0130" class="elsevierStyleSimplePara elsevierViewall">Clinical trials on prevention of anthracycline-induced cardiomyopathy&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:62 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Projections of global mortality and burden of disease from 2002 to 2030"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "C&#46;D&#46; Mathers"
                            1 => "D&#46; Loncar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1371/journal.pmed.0030442"
                      "Revista" => array:5 [
                        "tituloSerie" => "PLoS Med"
                        "fecha" => "2006"
                        "volumen" => "3"
                        "paginaInicial" => "e442"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17132052"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "EACVI&#47;HFA Cardiac Oncology Toxicity Registry in breast cancer patients&#58; rationale&#44; study design&#44; and methodology &#40;EACVI&#47;HFACOT Registry&#41; &#8211; EURObservational Research Program of the European Society of Cardiology"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "P&#46; Lancellotti"
                            1 => "S&#46;D&#46; Anker"
                            2 => "E&#46; Donal"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Am Soc Echocardiogr"
                        "fecha" => "2015"
                        "volumen" => "16"
                        "paginaInicial" => "466"
                        "paginaFinal" => "470"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiotoxicity of anticancer drugs&#58; the need for cardio-oncology and cardio-oncological prevention"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "A&#46; Albini"
                            1 => "G&#46; Pennesi"
                            2 => "F&#46; Donatelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/jnci/djp440"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Natl Cancer Inst"
                        "fecha" => "2010"
                        "volumen" => "102"
                        "paginaInicial" => "14"
                        "paginaFinal" => "25"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20007921"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "D&#46; Cardinale"
                            1 => "M&#46;T&#46; Sandri"
                            2 => "A&#46; Martinoni"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Am Coll Cardiol"
                        "fecha" => "2000"
                        "volumen" => "36"
                        "paginaInicial" => "517"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10933366"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy&#58; a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "J&#46;C&#46; Plana"
                            1 => "M&#46; Galderisi"
                            2 => "A&#46; Barac"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.echo.2014.07.012"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Soc Echocardiogr"
                        "fecha" => "2014"
                        "volumen" => "27"
                        "paginaInicial" => "911"
                        "paginaFinal" => "939"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25172399"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Management of chemotherapy induced cardiomyopathy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46; Saidi"
                            1 => "R&#46; Alharethi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "Curr Cardiol Rev"
                        "fecha" => "2011"
                        "volumen" => "7"
                        "paginaInicial" => "245"
                        "paginaFinal" => "249"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22758625"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0039606015003177"
                          "estado" => "S300"
                          "issn" => "00396060"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "AHA&#47;ACCF&#47;HRS recommendations for the standardization and interpretation of the electrocardiogram&#58; Part IV&#58; The ST segment&#44; T and U waves&#44; and the QT interval&#58; a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee&#44; Council on Clinical Cardiology&#59; the American College of Cardiology Foundation&#59; and the Heart Rhythm Society&#46; Endorsed by the International Society for Computerized Electrocardiology"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "P&#46;M&#46; Rautaharju"
                            1 => "B&#46; Surawicz"
                            2 => "L&#46;S&#46; Gettes"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jacc.2008.12.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Coll Cardiol"
                        "fecha" => "2009"
                        "volumen" => "53"
                        "paginaInicial" => "982"
                        "paginaFinal" => "991"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19281931"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Chemotherapy-induced cardiotoxicity&#58; detection&#44; prevention&#44; and management"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "J&#46; Truong"
                            1 => "A&#46;T&#46; Yan"
                            2 => "G&#46; Cramarossa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cjca.2014.04.029"
                      "Revista" => array:6 [
                        "tituloSerie" => "Can J Cardiol"
                        "fecha" => "2014"
                        "volumen" => "30"
                        "paginaInicial" => "869"
                        "paginaFinal" => "878"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25064580"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Doxorubicin-induced congestive heart failure in adults"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "M&#46;M&#46; Haq"
                            1 => "S&#46;S&#46; Legha"
                            2 => "J&#46; Choksi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer"
                        "fecha" => "1985"
                        "volumen" => "56"
                        "paginaInicial" => "1361"
                        "paginaFinal" => "1365"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/4027874"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiac diastolic function in pediatric patients receiving doxorubicin"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "M&#46;S&#46; Ewer"
                            1 => "M&#46;K&#46; Ali"
                            2 => "H&#46;R&#46; Gibbs"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Acta Oncol"
                        "fecha" => "1994"
                        "volumen" => "33"
                        "paginaInicial" => "645"
                        "paginaFinal" => "649"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7946442"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Early detection of doxorubicin cardiotoxicity&#58; interest of Doppler echocardiographic analysis of left ventricular filling dynamics"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "B&#46; Marchandise"
                            1 => "E&#46; Schroeder"
                            2 => "A&#46; Bosly"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Am Heart J"
                        "fecha" => "1989"
                        "volumen" => "118"
                        "paginaInicial" => "92"
                        "paginaFinal" => "98"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2741800"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Anticancer drugs and cardiotoxicity&#58; insights and perspectives in the era of targeted therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "E&#46; Raschi"
                            1 => "V&#46; Vasina"
                            2 => "M&#46;G&#46; Ursino"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.pharmthera.2009.10.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pharmacol Ther"
                        "fecha" => "2010"
                        "volumen" => "125"
                        "paginaInicial" => "196"
                        "paginaFinal" => "218"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19874849"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "R&#46;G&#46; Schwartz"
                            1 => "D&#46; Jain"
                            2 => "E&#46; Storozynsky"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s12350-013-9707-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Nucl Cardiol"
                        "fecha" => "2013"
                        "volumen" => "20"
                        "paginaInicial" => "443"
                        "paginaFinal" => "464"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23572315"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Early detection of treatment induced cardiac toxicity &#8211; can we do better&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "J&#46;M&#46; Lombard"
                            1 => "R&#46; Paterson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ajco.12085"
                      "Revista" => array:6 [
                        "tituloSerie" => "Asia Pac J Clin Oncol"
                        "fecha" => "2013"
                        "volumen" => "9"
                        "paginaInicial" => "97"
                        "paginaFinal" => "98"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23682667"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer&#58; current evidence and underlying mechanisms"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "J&#46;M&#46; Scott"
                            1 => "A&#46; Khakoo"
                            2 => "J&#46;R&#46; Mackey"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1161/CIRCULATIONAHA.111.021774"
                      "Revista" => array:6 [
                        "tituloSerie" => "Circulation"
                        "fecha" => "2011"
                        "volumen" => "124"
                        "paginaInicial" => "642"
                        "paginaFinal" => "650"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21810673"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "A&#46;J&#46; Chicco"
                            1 => "D&#46;S&#46; Hydock"
                            2 => "C&#46;M&#46; Schneider"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Appl Physiol &#40;Bethesda&#44; MD&#58; 1985&#41;"
                        "fecha" => "2006"
                        "volumen" => "100"
                        "paginaInicial" => "519"
                        "paginaFinal" => "527"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Randomized controlled trial of exercise training in postmenopausal breast cancer survivors&#58; cardiopulmonary and quality of life outcomes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "K&#46;S&#46; Courneya"
                            1 => "J&#46;R&#46; Mackey"
                            2 => "G&#46;J&#46; Bell"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2003.04.093"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2003"
                        "volumen" => "21"
                        "paginaInicial" => "1660"
                        "paginaFinal" => "1668"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12721239"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "L&#46;W&#46; Jones"
                            1 => "N&#46;D&#46; Eves"
                            2 => "M&#46; Haykowsky"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S1470-2045(09)70031-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Oncol"
                        "fecha" => "2009"
                        "volumen" => "10"
                        "paginaInicial" => "598"
                        "paginaFinal" => "605"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19482248"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Molecularly targeted oncology therapeutics and prolongation of the QT interval"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "E&#46;L&#46; Strevel"
                            1 => "D&#46;J&#46; Ing"
                            2 => "L&#46;L&#46; Siu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2006.09.6925"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2007"
                        "volumen" => "25"
                        "paginaInicial" => "3362"
                        "paginaFinal" => "3371"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17664484"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "interval prolongation in cancer patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "T&#46;K&#46; Becker"
                            1 => "S&#46;C&#46;J&#46; Yeung"
                            2 => "Q&#46;T&#46; Drug-induced"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Oncol Rev"
                        "fecha" => "2010"
                        "volumen" => "4"
                        "paginaInicial" => "223"
                        "paginaFinal" => "232"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiovascular toxicity induced by chemotherapy&#44; targeted agents and radiotherapy&#58; ESMO clinical practice guidelines"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "G&#46; Curigliano"
                            1 => "D&#46; Cardinale"
                            2 => "T&#46; Suter"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/annonc/mds293"
                      "Revista" => array:7 [
                        "tituloSerie" => "Ann Oncol"
                        "fecha" => "2012"
                        "volumen" => "23"
                        "numero" => "Suppl&#46; 7"
                        "paginaInicial" => "vii155"
                        "paginaFinal" => "vii166"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22997448"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Congestive heart failure in patients treated with doxorubicin&#58; a retrospective analysis of three trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "S&#46;M&#46; Swain"
                            1 => "F&#46;S&#46; Whaley"
                            2 => "M&#46;S&#46; Ewer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cncr.11407"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer"
                        "fecha" => "2003"
                        "volumen" => "97"
                        "paginaInicial" => "2869"
                        "paginaFinal" => "2879"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12767102"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiovascular complications of cancer therapy&#58; diagnosis&#44; pathogenesis&#44; and management"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "E&#46;T&#46; Yeh"
                            1 => "A&#46;T&#46; Tong"
                            2 => "D&#46;J&#46; Lenihan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1161/01.CIR.0000133187.74800.B9"
                      "Revista" => array:7 [
                        "tituloSerie" => "Circulation&#46;"
                        "fecha" => "2004"
                        "volumen" => "109"
                        "numero" => "25"
                        "paginaInicial" => "3122"
                        "paginaFinal" => "3131"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15226229"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiotoxicity associated with cancer therapy&#58; pathophysiology and prevention strategies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "R&#46; Ad&#227;o"
                            1 => "G&#46; de Keulenaer"
                            2 => "A&#46; Leite-Moreira"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.repc.2012.11.002"
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Port Cardiol"
                        "fecha" => "2013"
                        "volumen" => "32"
                        "paginaInicial" => "395"
                        "paginaFinal" => "409"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23623503"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "S&#46;S&#46; Legha"
                            1 => "R&#46;S&#46; Benjamin"
                            2 => "B&#46; Mackay"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Intern Med"
                        "fecha" => "1982"
                        "volumen" => "96"
                        "paginaInicial" => "133"
                        "paginaFinal" => "139"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7059060"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Continuous versus bolus infusion of doxorubicin in children with ALL&#58; long-term cardiac outcomes"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "S&#46;E&#46; Lipshultz"
                            1 => "T&#46;L&#46; Miller"
                            2 => "S&#46;R&#46; Lipsitz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1542/peds.2012-0727"
                      "Revista" => array:6 [
                        "tituloSerie" => "Pediatrics"
                        "fecha" => "2012"
                        "volumen" => "130"
                        "paginaInicial" => "1003"
                        "paginaFinal" => "1011"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23166343"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer&#58; a prospective&#44; randomized study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "M&#46; Valdivieso"
                            1 => "M&#46;A&#46; Burgess"
                            2 => "M&#46;S&#46; Ewer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.1984.2.3.207"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "1984"
                        "volumen" => "2"
                        "paginaInicial" => "207"
                        "paginaFinal" => "214"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/6321689"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "M&#46;A&#46; Pacciarini"
                            1 => "B&#46; Barbieri"
                            2 => "T&#46; Colombo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Treat Rep"
                        "fecha" => "1978"
                        "volumen" => "62"
                        "paginaInicial" => "791"
                        "paginaFinal" => "800"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/657163"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "CD003917"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardioprotective interventions for cancer patients receiving anthracyclines"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "E&#46;C&#46; van Dalen"
                            1 => "H&#46;N&#46; Caron"
                            2 => "H&#46;O&#46; Dickinson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/14651858.CD003917.pub4"
                      "Revista" => array:2 [
                        "tituloSerie" => "Cochrane Database Syst Rev"
                        "fecha" => "2011"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "S&#46; Hamed"
                            1 => "I&#46; Barshack"
                            2 => "G&#46; Luboshits"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/eurheartj/ehl044"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur Heart J"
                        "fecha" => "2006"
                        "volumen" => "27"
                        "paginaInicial" => "1876"
                        "paginaFinal" => "1883"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16731534"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "F&#46;M&#46; Muggia"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:7 [
                        "tituloSerie" => "Drugs"
                        "fecha" => "1997"
                        "volumen" => "54"
                        "numero" => "Suppl&#46; 4"
                        "paginaInicial" => "22"
                        "paginaFinal" => "29"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9361958"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "CD005006"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Different anthracycline derivates for reducing cardiotoxicity in cancer patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "E&#46;C&#46; van Dalen"
                            1 => "E&#46;M&#46; Michiels"
                            2 => "H&#46;N&#46; Caron"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/14651858.CD005006.pub3"
                      "Revista" => array:2 [
                        "tituloSerie" => "Cochrane Database Syst Rev"
                        "fecha" => "2010"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "U&#46;S&#46; Food and Drug Administration&#46; Drug safety and availability&#46; FDA statement on DOXIL<span class="elsevierStyleSup">&#174;</span> &#40;doxorubicin HCl liposome injection&#41; for intravenous infusion&#46; Available at&#58; <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050718s043lbl.pdf">http&#58;&#47;&#47;www&#46;accessdata&#46;fda&#46;gov&#47;drugsatfda&#95;docs&#47;label&#47;2012&#47;050718s043lbl&#46;pdf</a> &#91;accessed 27&#46;01&#46;15&#93;&#46;"
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "M&#46;L&#46; Hensley"
                            1 => "L&#46;M&#46; Schuchter"
                            2 => "C&#46; Lindley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.1999.17.10.3333"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "1999"
                        "volumen" => "17"
                        "paginaInicial" => "3333"
                        "paginaFinal" => "3355"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10506637"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "E&#46; Martin"
                            1 => "A&#46;V&#46; Thougaard"
                            2 => "M&#46; Grauslund"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.tox.2008.10.011"
                      "Revista" => array:6 [
                        "tituloSerie" => "Toxicology"
                        "fecha" => "2009"
                        "volumen" => "255"
                        "paginaInicial" => "72"
                        "paginaFinal" => "79"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19010377"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The oral iron chelator ICL670A &#40;deferasirox&#41; does not protect myocytes against doxorubicin"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "B&#46;B&#46; Hasinoff"
                            1 => "D&#46; Patel"
                            2 => "X&#46; Wu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Free Radic Biol Med"
                        "fecha" => "2003"
                        "volumen" => "35"
                        "paginaInicial" => "1469"
                        "paginaFinal" => "1479"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14642395"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Topoisomerase IIbeta mediated DNA double-strand breaks&#58; implications in doxorubicin cardiotoxicity and prevention by dexrazoxane"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "Y&#46;L&#46; Lyu"
                            1 => "J&#46;E&#46; Kerrigan"
                            2 => "C&#46;P&#46; Lin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1158/0008-5472.CAN-07-1649"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Res"
                        "fecha" => "2007"
                        "volumen" => "67"
                        "paginaInicial" => "8839"
                        "paginaFinal" => "8846"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17875725"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "S&#46;E&#46; Lipshultz"
                            1 => "N&#46; Rifai"
                            2 => "V&#46;M&#46; Dalton"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1056/NEJMoa035153"
                      "Revista" => array:6 [
                        "tituloSerie" => "N Engl J Med"
                        "fecha" => "2004"
                        "volumen" => "351"
                        "paginaInicial" => "145"
                        "paginaFinal" => "153"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15247354"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia&#58; long-term follow-up of a prospective&#44; randomised&#44; multicentre trial"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "S&#46;E&#46; Lipshultz"
                            1 => "R&#46;E&#46; Scully"
                            2 => "S&#46;R&#46; Lipsitz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S1470-2045(10)70204-7"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet Oncol"
                        "fecha" => "2010"
                        "volumen" => "11"
                        "paginaInicial" => "950"
                        "paginaFinal" => "961"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20850381"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001&#58; a report from the children&#39;s oncology group"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "W&#46;L&#46; Salzer"
                            1 => "M&#46; Devidas"
                            2 => "W&#46;L&#46; Carroll"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/leu.2009.261"
                      "Revista" => array:6 [
                        "tituloSerie" => "Leukemia"
                        "fecha" => "2010"
                        "volumen" => "24"
                        "paginaInicial" => "355"
                        "paginaFinal" => "370"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20016527"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia&#58; a report from the Dana-Farber Cancer Institute ALL Consortium"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "L&#46;M&#46; Vrooman"
                            1 => "D&#46;S&#46; Neuberg"
                            2 => "K&#46;E&#46; Stevenson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ejca.2011.03.022"
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Cancer"
                        "fecha" => "2011"
                        "volumen" => "47"
                        "paginaInicial" => "1373"
                        "paginaFinal" => "1379"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21514146"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "FDA Statement on Dexrazoxane&#59; 2011&#46; Available at&#58; <a href="http://www.fda.gov/Drugs/DrugSafety/ucm263729.htm">http&#58;&#47;&#47;www&#46;fda&#46;gov&#47;Drugs&#47;DrugSafety&#47;ucm263729&#46;htm</a> &#91;cited 28&#46;02&#46;15&#93;&#46;"
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "P&#46; Spallarossa"
                            1 => "S&#46; Garibaldi"
                            2 => "P&#46; Altieri"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.yjmcc.2004.05.024"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Mol Cell Cardiol"
                        "fecha" => "2004"
                        "volumen" => "37"
                        "paginaInicial" => "837"
                        "paginaFinal" => "846"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15380674"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "N&#46;A&#46; El-Shitany"
                            1 => "O&#46;A&#46; Tolba"
                            2 => "M&#46;R&#46; El-Shanshory"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.cardfail.2012.06.416"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Card Fail"
                        "fecha" => "2012"
                        "volumen" => "18"
                        "paginaInicial" => "607"
                        "paginaFinal" => "613"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22858075"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R&#46; Garg"
                            1 => "S&#46; Yusuf"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Am Med Assoc"
                        "fecha" => "1995"
                        "volumen" => "273"
                        "paginaInicial" => "1450"
                        "paginaFinal" => "1456"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effects of controlled-release metoprolol on total mortality&#44; hospitalizations&#44; and well-being in patients with heart failure&#58; the metoprolol CR&#47;XL randomized intervention trial in congestive heart failure &#40;MERIT-HF&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "A&#46; Hjalmarson"
                            1 => "S&#46; Goldstein"
                            2 => "B&#46; Fagerberg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Am Med Assoc"
                        "fecha" => "2000"
                        "volumen" => "283"
                        "paginaInicial" => "1295"
                        "paginaFinal" => "1302"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients&#58; a prospective&#44; parallel-group&#44; randomized&#44; controlled study with 36-month follow-up"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "P&#46; Georgakopoulos"
                            1 => "P&#46; Roussou"
                            2 => "E&#46; Matsakas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/ajh.21840"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Hematol"
                        "fecha" => "2010"
                        "volumen" => "85"
                        "paginaInicial" => "894"
                        "paginaFinal" => "896"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20872550"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "H&#46; Toko"
                            1 => "T&#46; Oka"
                            2 => "Y&#46; Zou"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Hypertens Res"
                        "fecha" => "2002"
                        "volumen" => "25"
                        "paginaInicial" => "597"
                        "paginaFinal" => "603"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12358147"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "J&#46;H&#46; Silber"
                            1 => "A&#46; Cnaan"
                            2 => "B&#46;J&#46; Clark"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2004.06.022"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2004"
                        "volumen" => "22"
                        "paginaInicial" => "820"
                        "paginaFinal" => "828"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14990637"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "D&#46; Cardinale"
                            1 => "A&#46; Colombo"
                            2 => "M&#46;T&#46; Sandri"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1161/CIRCULATIONAHA.106.635144"
                      "Revista" => array:6 [
                        "tituloSerie" => "Circulation"
                        "fecha" => "2006"
                        "volumen" => "114"
                        "paginaInicial" => "2474"
                        "paginaFinal" => "2481"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17101852"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Notable effects of angiotensin II receptor blocker&#44; valsartan&#44; on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide&#44; doxorubicin&#44; vincristine&#44; and prednisolone"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "H&#46; Nakamae"
                            1 => "K&#46; Tsumura"
                            2 => "Y&#46; Terada"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cncr.21478"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer"
                        "fecha" => "2005"
                        "volumen" => "104"
                        "paginaInicial" => "2492"
                        "paginaFinal" => "2498"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16247790"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:3 [
                  "comentario" => "487&#46;e1&#8211;7"
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation&#44; oxidative stress&#44; and early ventricular impairment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "C&#46; Cadeddu"
                            1 => "A&#46; Piras"
                            2 => "G&#46; Mantovani"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Am Heart J"
                        "fecha" => "2010"
                        "volumen" => "160"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "A&#46; Riad"
                            1 => "S&#46; Bien"
                            2 => "D&#46; Westermann"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1158/0008-5472.CAN-08-3076"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer Res"
                        "fecha" => "2009"
                        "volumen" => "69"
                        "paginaInicial" => "695"
                        "paginaFinal" => "699"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19147586"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy&#58; an observational clinical cohort study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "S&#46; Seicean"
                            1 => "A&#46; Seicean"
                            2 => "J&#46;C&#46; Plana"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jacc.2012.07.067"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Coll Cardiol"
                        "fecha" => "2012"
                        "volumen" => "60"
                        "paginaInicial" => "2384"
                        "paginaFinal" => "2390"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23141499"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "Z&#46; Acar"
                            1 => "A&#46; Kale"
                            2 => "M&#46; Turgut"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jacc.2011.05.025"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Coll Cardiol"
                        "fecha" => "2011"
                        "volumen" => "58"
                        "paginaInicial" => "988"
                        "paginaFinal" => "989"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21851890"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease&#58; ESMO clinical practice guidelines"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "D&#46; Bovelli"
                            1 => "G&#46; Plataniotis"
                            2 => "F&#46; Roila"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/annonc/mdq200"
                      "Revista" => array:7 [
                        "tituloSerie" => "Ann Oncol"
                        "fecha" => "2010"
                        "volumen" => "21"
                        "numero" => "Suppl&#46; 5"
                        "paginaInicial" => "v277"
                        "paginaFinal" => "v282"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20555097"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Anthracycline-induced cardiomyopathy&#46; Clinical relevance and response to pharmacologic therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "D&#46; Cardinale"
                            1 => "A&#46; Colombo"
                            2 => "G&#46; Lamantia"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jacc.2009.03.095"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Coll Cardiol"
                        "fecha" => "2010"
                        "volumen" => "55"
                        "paginaInicial" => "213"
                        "paginaFinal" => "220"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20117401"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            57 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "58"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Supercoiling of the DNA template during transcription"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "L&#46;F&#46; Liu"
                            1 => "J&#46;C&#46; Wang"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Proc Natl Acad Sci U S A"
                        "fecha" => "1987"
                        "volumen" => "84"
                        "paginaInicial" => "7024"
                        "paginaFinal" => "7027"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2823250"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            58 => array:3 [
              "identificador" => "bib0295"
              "etiqueta" => "59"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Carvedilol as a protector against the cardiotoxicity induced by anthracyclines &#40;doxorubicin&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "V&#46; Machado"
                            1 => "A&#46; Cabral"
                            2 => "P&#46; Monteiro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Port Cardiol"
                        "fecha" => "2008"
                        "volumen" => "27"
                        "paginaInicial" => "1277"
                        "paginaFinal" => "1296"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19178029"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            59 => array:3 [
              "identificador" => "bib0300"
              "etiqueta" => "60"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiac dysfunction in the trastuzumab clinical trials experience"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "A&#46; Seidman"
                            1 => "C&#46; Hudis"
                            2 => "M&#46;K&#46; Pierri"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2002.20.5.1215"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2002"
                        "volumen" => "20"
                        "paginaInicial" => "1215"
                        "paginaFinal" => "1221"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11870163"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            60 => array:3 [
              "identificador" => "bib0305"
              "etiqueta" => "61"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Noninvasive imaging of cardiovascular injury related to the treatment of cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "S&#46; Kongbundansuk"
                            1 => "W&#46;G&#46; Hundley"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Am Coll Cardiol Imaging"
                        "fecha" => "2014"
                        "volumen" => "7"
                        "paginaInicial" => "824"
                        "paginaFinal" => "838"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            61 => array:3 [
              "identificador" => "bib0310"
              "etiqueta" => "62"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Normal range of left ventricular 2-dimensional strain&#58; Japanese Ultrasound Speckle Tracking of the Left Ventricle &#40;JUSTICE&#41; study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:3 [
                            0 => "K&#46; Takigiku"
                            1 => "M&#46; Takeuchi"
                            2 => "C&#46; Izumi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Circ J"
                        "fecha" => "2012"
                        "volumen" => "76"
                        "paginaInicial" => "2623"
                        "paginaFinal" => "2632"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22813873"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/21742049/0000003500000006/v2_201704050129/S2174204916300642/v2_201704050129/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "9924"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Review Article"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/21742049/0000003500000006/v2_201704050129/S2174204916300642/v2_201704050129/en/main.pdf?idApp=UINPBA00004E&text.app=https://revportcardiol.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2174204916300642?idApp=UINPBA00004E"
]

Article information

ISSN: 21742049
Original language: English

DOI:10.1016/j.repce.2015.12.020

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	10	10	20
2024 October	60	48	108
2024 September	65	33	98
2024 August	60	38	98
2024 July	67	29	96
2024 June	52	36	88
2024 May	96	30	126
2024 April	44	25	69
2024 March	57	23	80
2024 February	27	36	63
2024 January	35	41	76
2023 December	27	34	61
2023 November	46	24	70
2023 October	28	19	47
2023 September	25	24	49
2023 August	27	23	50
2023 July	33	10	43
2023 June	34	21	55
2023 May	42	25	67
2023 April	30	15	45
2023 March	75	24	99
2023 February	58	19	77
2023 January	34	13	47
2022 December	35	19	54
2022 November	71	32	103
2022 October	41	20	61
2022 September	29	28	57
2022 August	30	36	66
2022 July	46	47	93
2022 June	26	40	66
2022 May	34	27	61
2022 April	41	30	71
2022 March	31	29	60
2022 February	33	28	61
2022 January	42	26	68
2021 December	32	28	60
2021 November	49	40	89
2021 October	35	35	70
2021 September	57	35	92
2021 August	66	31	97
2021 July	60	30	90
2021 June	52	23	75
2021 May	64	34	98
2021 April	157	100	257
2021 March	212	44	256
2021 February	131	23	154
2021 January	125	33	158
2020 December	123	27	150
2020 November	89	17	106
2020 October	94	35	129
2020 September	100	21	121
2020 August	79	11	90
2020 July	118	20	138
2020 June	105	9	114
2020 May	108	22	130
2020 April	95	16	111
2020 March	134	20	154
2020 February	173	46	219
2020 January	71	17	88
2019 December	168	11	179
2019 November	106	19	125
2019 October	145	11	156
2019 September	135	10	145
2019 August	82	16	98
2019 July	88	17	105
2019 June	68	23	91
2019 May	86	30	116
2019 April	62	24	86
2019 March	165	27	192
2019 February	127	11	138
2019 January	97	38	135
2018 December	123	15	138
2018 November	258	16	274
2018 October	707	24	731
2018 September	107	22	129
2018 August	124	53	177
2018 July	52	18	70
2018 June	84	21	105
2018 May	125	38	163
2018 April	149	39	188
2018 March	66	26	92
2018 February	45	17	62
2018 January	35	18	53
2017 December	59	20	79
2017 November	76	38	114
2017 October	59	24	83
2017 September	48	31	79
2017 August	60	26	86
2017 July	35	19	54
2017 June	56	37	93
2017 May	79	15	94
2017 April	46	11	57
2017 March	45	34	79
2017 February	74	11	85
2017 January	46	16	62
2016 December	56	20	76
2016 November	45	22	67
2016 October	52	33	85
2016 September	47	28	75
2016 August	12	4	16
2016 July	52	52	104
2016 June	6	110	116

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter